<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1903233380
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Oxbryta
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VOXELOTOR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        90
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        26683.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PATHEON INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PATHEON INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Global Blood Therapeutics
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Oxbryta is a hemoglobin S polymerization inhibitor used for the treatment of sickle cell disease in adults and children 12 years of age and older.</p><p>&nbsp;</p><p>It is not known if Oxbryta is safe and effective in children below 12 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp; </strong><strong>Do not take Oxbryta</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had an allergic reaction to voxelotor or any of the ingredients in Oxbryta. See &ldquo;Further information&rdquo; section in this leaflet for a list of the ingredients in Oxbryta.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are receiving exchange transfusions, talk to your healthcare provider about possible difficulties with the interpretation of certain blood tests when taking Oxbryta.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxbryta is not recommended for children under 12 years due to insufficient data in this age group.</p><p>&nbsp;</p><p>b.&nbsp; Take special care with Oxbryta</p><p>Tell your healthcare provider about all of your medical conditions, including liver problems before taking Oxbryta.</p><p>&nbsp;</p><p>Contact your doctor or healthcare provider immediately if you get a rash, hives, swollen face or have difficulty breathing after you take Oxbryta.</p><p>&nbsp;</p><p>c.&nbsp; Taking other medicines, herbal or dietary supplements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your healthcare provider about all the medicines you take, including prescription and over- the-counter medicines, vitamins, and herbal supplements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines may affect how Oxbryta works.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxbryta may also affect how other medicines work.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep a list of all your medicines and show it to your healthcare provider.</p><p>&nbsp;</p><p>d.&nbsp; Taking Oxbryta with food and drink</p><p>Oxbryta can be taken with or without food.</p><p>&nbsp;</p><p>e.&nbsp; Pregnancy and breast-feeding</p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or healthcare provided for advice before taking this medicine. It is not known if Oxbryta can harm your unborn baby.</p><p>&nbsp;</p><p>If you are breast-feeding or planning to breast-feed, ask your doctor or healthcare provider for advice before taking this medicine. It is not known if Oxbryta can pass into your breastmilk and if it can harm your baby.</p><p>&nbsp;</p><p>f.&nbsp; Driving and using machines</p><p>Oxbryta has no effect on driving and using machines.</p><p>&nbsp;</p><p>g.&nbsp; Important information about some of the ingredients of Oxbryta Oxbryta contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per dose of three tablets, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Oxbryta exactly as your health care provider has told you. Do not change your dose or stop taking Oxbryta unless your doctor or healthcare provider tells you to. Check with your doctor or healthcare provider if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take OXBRYTA 1 time each day. Swallow each Oxbryta tablet whole. Do not cut, crush or chew the tablets.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Oxbryta with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or healthcare provider may change your dose if needed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or healthcare provider may also prescribe hydroxyurea during treatment with Oxbryta.</p><p>&nbsp;</p><p>a.&nbsp; If you take more Oxbryta than you should</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact your doctor or healthcare provider immediately.</p><p>&nbsp;</p><p>b.&nbsp; If you forget to take Oxbryta</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skip that dose and return to your normal dosing schedule the next day.</p><p>&nbsp;</p><p>c.&nbsp; If you stop taking Oxbryta</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not change your dose or stop taking Oxbryta unless your doctor or healthcare provider tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or healthcare provider.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Oxbryta can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious allergic reactions (may affect up to 1 in 100 people): </strong>Contact your doctor or healthcare provider or get emergency medical help immediately if you have one or more of the following side effects:</p><p>o rash</p><p>o hives</p><p>o shortness of breath</p><p>o swelling of the face</p><p>&nbsp;</p><p>Very common side effects (may affect more than 1 in 10 people)</p><p>o diarrhoea</p><p>o abdominal pain</p><p>o nausea</p><p>o headache</p><p>o rash</p><p>o tiredness</p><p>o fever</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor or healthcare provider or get emergency medical help right away if you get serious allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These are not all the possible side effects of Oxbryta.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call your doctor or healthcare provider for medical advice about side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or healthcare provider.</p><p>&nbsp;</p><p><strong>a.&nbsp; </strong><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_1" o:spid="_x0000_s1029" style='position:absolute;
  margin-left:71.9pt;margin-top:6.7pt;width:282pt;height:72.25pt;z-index:-15728640;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordsize="35814,9175" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Graphic_x0020_2" o:spid="_x0000_s1030" style='position:absolute;
   width:35814;height:9175;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="3581400,917575" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m3442716,917448r-3304032,l108204,911352,68580,891540,36576,861060,27432,850392,12192,822960,7620,809244,1524,778764,,763524,,153924,7620,108204,27432,68580,56388,35052,94488,12192,155448,,3427476,r30480,3048l155448,3048,138684,4572,96012,15240,59436,38100,47244,47244r1524,l38100,57912,28956,70104,10668,109728,4572,138684r,640080l10668,809244r457,l15240,822960r6096,12192l28956,847344r9144,12192l48768,870204r-1524,l59436,880872r1778,l70104,888492r12192,7620l109728,908304r15240,3048l123444,911352r15240,3048l3457956,914400r-15240,3048xem3573780,809244r-3048,l3575304,794004r3048,-30480l3578352,153924r-3048,-30480l3560064,82296,3534156,47244r-12192,-9144l3523488,38100,3485388,15240,3456432,6096r1524,l3427476,3048r30480,l3500628,18288r45720,38100l3569208,94488r12192,59436l3581400,763524r-3048,30480l3573780,809244xem11125,809244r-457,l10668,807720r457,1524xem3526790,880872r-4826,l3534156,870204r9144,-10668l3552444,847344r7620,-12192l3566160,822960r4572,-15240l3570732,809244r3048,l3569208,822960r-15240,27432l3546348,861060r-10668,12192l3526790,880872xem61214,880872r-1778,l59436,879348r1778,1524xem3457956,914400r-15240,l3457956,911352r-1524,l3471672,908304r27432,-12192l3511296,888492r12192,-9144l3521964,880872r4826,l3525012,882396r-12192,9144l3500628,899160r-27432,12192l3457956,914400xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
   path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Textbox_x0020_3" o:spid="_x0000_s1031" type="#_x0000_t202"
   style='position:absolute;width:35814;height:9175;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.45pt'><b style='mso-bidi-font-weight:
      normal'><span style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><o:p>&nbsp;</o:p></span></b></p>
      <p class=MsoNormal style='margin-left:16.95pt;text-indent:-6.05pt;
      mso-list:l0 level1 lfo1;tab-stops:16.95pt'><![if !supportLists]><span
      style='font-size:10.0pt;mso-font-width:99%'><span style='mso-list:Ignore'>-<span
      style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
      dir=LTR></span><span style='font-size:10.0pt;mso-bidi-font-size:11.0pt'>National<span
      style='letter-spacing:-.55pt'> </span>Pharmacovigilance<span
      style='letter-spacing:-.5pt'> </span>Center<span style='letter-spacing:
      -.5pt'> </span><span style='letter-spacing:-.1pt'>(NPC)</span><o:p></o:p></span></p>
      <p class=MsoNormal style='margin-top:.1pt;margin-right:0in;margin-bottom:
      0in;margin-left:46.9pt;margin-bottom:.0001pt;text-indent:-.25in;
      line-height:12.25pt;mso-line-height-rule:exactly;mso-list:l0 level2 lfo1;
      tab-stops:46.9pt'><![if !supportLists]><span style='font-size:10.0pt;
      font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
      Symbol;mso-font-width:99%'><span style='mso-list:Ignore'>·<span
      style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </span></span></span><![endif]><span dir=LTR></span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;letter-spacing:-.1pt'>Fax:</span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;letter-spacing:.6pt'> </span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;letter-spacing:-.1pt'>+966-1-210-</span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;letter-spacing:-.2pt'>7398</span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
      <p class=MsoNormal style='margin-left:46.9pt;text-indent:-.25in;
      line-height:12.2pt;mso-line-height-rule:exactly;mso-list:l0 level2 lfo1;
      tab-stops:46.9pt'><![if !supportLists]><span style='font-size:10.0pt;
      font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
      Symbol;mso-font-width:99%'><span style='mso-list:Ignore'>·<span
      style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </span></span></span><![endif]><span dir=LTR></span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt'>E-mail:<span
      style='letter-spacing:-.25pt'> </span></span><a
      href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:10.0pt;
      mso-bidi-font-size:11.0pt;color:windowtext;letter-spacing:-.1pt;
      text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
      <p class=MsoNormal style='margin-left:46.9pt;text-indent:-.25in;
      line-height:12.2pt;mso-line-height-rule:exactly;mso-list:l0 level2 lfo1;
      tab-stops:46.9pt'><![if !supportLists]><span style='font-size:10.0pt;
      font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
      Symbol;mso-font-width:99%'><span style='mso-list:Ignore'>·<span
      style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </span></span></span><![endif]><span dir=LTR></span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt'>Website:<span
      style='letter-spacing:-.45pt'> </span></span><a
      href="http://www.sfda.gov.sa/npc"><span style='font-size:10.0pt;
      mso-bidi-font-size:11.0pt;color:#0000FD;letter-spacing:-.1pt'>www.sfda.gov.sa/npc</span></a><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p>-&nbsp; National Pharmacovigilance Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-1-210-7398</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p>- Please contact the relevant competent authority.</p><p>&nbsp;</p></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Oxbryta at or below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxbryta comes in a child-resistant package.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The bottle contains a desiccant to help keep your medicine dry (protect it from moisture) and polyester coil. Do not eat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Oxbryta after the expiry date which is stated on the bottle after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp; </strong><strong>What Oxbryta contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is voxelotor. One tablet contains 500 mg voxelotor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>o colloidal silicon dioxide</p><p>o croscarmellose sodium</p><p>o magnesium stearate</p><p>o microcrystalline cellulose</p><p>o sodium lauryl sulphate</p><p>o polyethylene glycol 3350</p><p>o polyvinyl alcohol</p><p>o talc</p><p>o titanium dioxide</p><p>o iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oxbryta film-coated tablets are light yellow to yellow, oval-shaped tablets, stamped with “GBT 500” on one side.

Oxbryta is packaged in a plastic bottle with a child-resistant cap. Each bottle contains 90 film coated tablets. The bottle also contains coil and a silica gel desiccant canister to help keep your medicine dry. Do not eat or remove the canister from the bottle.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Marketing Authorisation Holder Global Blood Therapeutics, Inc.</p><p>181 Oyster Point Boulevard, Suite 300 South San Francisco, CA 94080</p><p>USA</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manufacturer Patheon, Inc.</p><p>111 Consumers Drive Whitby, Ontario L1N 5Z5 Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                -
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">دواء أوﻛﺳﺑرﯾﺗﺎ ﻣﺛﺑط ﻟﻌﻣﻠﯾﺔ ﺑﻠﻣرة اﻟﮭﯾﻣوﺟﻠوﺑﯾن س وﯾﺳﺗﺧدم ﻟﻌﻼج ﻣرض ﺧﻼﯾﺎ اﻟدم اﻟﻣﻧﺟﻠﯾﺔ ﻓﻲ اﻟﺑﺎﻟﻐﯾن واﻷطﻔﺎل اﻟذﯾن ﯾﺑﻠﻐون ﻣن اﻟﻌﻣر 12 ﻋﺎﻣﺎ</p><p dir="RTL">أو أﻛﺛر.</p><p>&nbsp;</p><p dir="RTL">ﻣن ﻏﯾر اﻟﻣﻌروف إذا ﻛﺎن دواء أوﻛﺳﺑرﯾﺗﺎ آﻣﻧﺎ وﻓﻌﺎ ﻻ ﻓﻲ ﻋﻼج اﻷطﻔﺎل اﻟذﯾن ﺗﻘل أﻋﻣﺎرھم ﻋن 12 ﻋﺎﻣﺎ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ. ﻻ ﺗﺗﻧﺎول أوﻛﺳﺑرﯾﺗﺎ</p><p dir="RTL">&middot;&nbsp; إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺣﺳﺎﺳية&nbsp;ﺗﺟﺎه اﻟﻔوﻛﺳﯾﻠوﺗور أو ﺿد أي ﻣن ﻣﻛوﻧﺎت اﻟدواء. راﺟﻊ ﻗﺳم &quot;ﻣﻌﻠوﻣﺎت إﺿﺎﻓية&nbsp;ﻓﻲ هذه اﻟﻧﺷرة ﻟﻼطﻼع ﻋﻠﻰ</p><p dir="RTL">ﻗﺎﺋﻣﺔ ﻣﻛوﻧﺎت دواء أوﻛﺳﺑريتا.</p><p dir="RTL">&middot;&nbsp; إذا ﻛﻧت ﺗﺧﺿﻊ ﻹﺟراءات ﺗﺑدﯾل اﻟدم، ﺗﺣدث إﻟﻰ ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ اﻟذي ﯾﺗﺎﺑﻊ ﺣﺎﻟﺗك ﻋن اﻟﺻﻌوﺑﺎت اﻟﻣﻣﻛﻧﺔ اﻟﺗﻲ ﺗرﺗﺑط ﺑﺗﺄﺛير ﺗﻧﺎول</p><p dir="RTL">أوﻛﺳﺑرﯾﺗﺎ ﻋﻠﻰ ﻧﺗﺎﺋﺞ ﺗﺣﺎﻟيل دم ﻣﻌﯾﻧﺔ.</p><p dir="RTL">&middot;&nbsp; ﻻ يوﺻﻰ ﺑﺎﺳﺗﻌﻣﺎل أوﻛﺳﺑرﯾﺗﺎ ﻟﻸطﻔﺎل دون ﺳن 12 ﻋﺎﻣﺎ ﺑﺳﺑب ﻋدم ﻛﻔﺎية&nbsp;اﻟﺑياﻧﺎت ﺣول ھذه اﻟﻔﺋﺔ اﻟﻌﻣريةﺔ.</p><p>&nbsp;</p><p>ب. اﺗﺧذ اﻻﺣﺗياطﺎت اﻟﻼزﻣﺔ ﻋﻧد اﺳﺗﺧدام أوﻛﺳﺑرﯾﺗﺎ</p><p dir="RTL">ﯾﻧﺑﻐﻲ ﻗﺑل اﻟﺑدء ﻓﻲ ﺗﻧﺎول دواء أوﻛﺳﺑريتا&nbsp;إطﻼع اﻟطﺑﯾب اﻟﻣﺧﺗص ﻋﻠﻰ ﺟﻣيع&nbsp;اﻷﻣراض واﻟﺣﺎﻻت اﻟطﺑية&nbsp;اﻟﺗﻲ ﺗﻌﺎﻧﻲ ﻣﻧها، ﺑﻣﺎ ﻓﻲ ذﻟك ﻣﺷﻛﻼت اﻟﻛﺑد.</p><p>&nbsp;</p><p dir="RTL">اﺗﺻل ﺑطﺑيبك&nbsp;أو ﻣﻘدم اﻟرﻋﺎية&nbsp;اﻟﺻﺣية ﻋﻠﻰ اﻟﻔور إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن اﻟطﻔﺢ اﻟﺟﻠدي أو اﻟﺷرى أو ﺗورم ﺑﺎﻟوﺟه أو ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﻧﻔس ﺑﻌد ﺗﻧﺎول</p><p dir="RTL">أوﻛﺳﺑريتا.</p><p>&nbsp;</p><p>ج. ﺗﻧﺎول أدوﯾية أﺧرى أو ﻣﻛﻣﻼت ﻏذاﺋﯾﺔ أو ﻋﺷﺑﯾﺔ</p><p dir="RTL">&middot;&nbsp; أﺧﺑر طﺑﯾﺑك ﻋن ﺟﻣﯾﻊ اﻷدوﯾﺔ اﻟﺗﻲ ﺗﺳﺗﻌﻣﻠﮭﺎ، ﺑﻣﺎ ﻓﻲ ذﻟك اﻷدوﯾﺔ اﻟﻣوﺻوﻓﺔ طﺑﯾﺎ أو اﻟﻌﻘﺎﻗﯾر اﻟﻣﺗﺎﺣﺔ ﺑدون وﺻﻔﺔ طﺑﯾﺔ، واﻟﻔﯾﺗﺎﻣﯾﻧﺎت</p><p dir="RTL">واﻟﻣﻛﻣﻼت اﻟﻌﺷﺑﯾﺔ.</p><p dir="RTL">&middot;&nbsp; ﯾﻣﻛن أن ﺗؤﺛر ﺑﻌض اﻷدوﯾﺔ ﻋﻠﻰ ﻛﯾﻔﯾﺔ ﻋﻣل أوﻛﺳﺑرﯾﺗﺎ.</p><p dir="RTL">&middot;&nbsp; ﻛﻣﺎ ﯾﻣﻛن أن ﯾؤﺛر أوﻛﺳﺑرﯾﺗﺎ ﻋﻠﻰ ﻛﯾﻔﯾﺔ ﻋﻣل اﻷدوﯾﺔ اﻷﺧرى.</p><p dir="RTL">&middot;&nbsp; اﺣﺗﻔظ ﺑﻘﺎﺋﻣﺔ أدوﯾﺗك وأﻋرﺿﮭﺎ ﻋﻠﻰ ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ اﻟﻣﺗﺎﺑﻊ ﻟﺣﺎﻟﺗك.</p><p>&nbsp;</p><p>د. ﺗﻧﺎول أوﻛﺳﺑرﯾﺗﺎ ﻣﻊ اﻟطﻌﺎم أو ﺑدوﻧﮫ</p><p dir="RTL">ﯾﻣﻛن ﺗﻧﺎول ھذا اﻟدواء ﻣﻊ اﻟطﻌﺎم أو ﺑدوﻧﮫ.</p><p>&nbsp;</p><p>ھـ. اﻟﺣﻣل واﻟرﺿﺎﻋﺔ اﻟطﺑﯾﻌﯾﺔ</p><p dir="RTL">إذا ﻛﻧت ﻓﻲ ﻓﺗرة اﻟﺣﻣل، أو ﺗﻌﺗﻘدﯾن ﺑوﺟود ﺣﻣل أو ﺗﺧططﯾن ﻟﻺﻧﺟﺎب ﻓﺎﺳﺗﺷﯾري طﺑﯾﺑك أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ ﻗﺑل ﺗﻠﻘﻲ اﻟﻌﻼج ﺑﮭذا اﻟدواء. ﻣن ﻏﯾر</p><p dir="RTL">اﻟﻣﻌروف ﻣﺎ إذا ﻛﺎن اﺳﺗﺧدام أوﻛﺳﺑرﯾﺗﺎ ﻗد ﯾﺿر ﺑﺟﻧﯾﻧك.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">اذا كنت ﻓﻲ ﻓﺗرة اﻟرﺿﺎﻋﺔ، أو ﺗﺧططﯾن ﻟﻠرﺿﺎﻋﺔ اﻟطﺑﯾﻌﯾﺔ ﻓﺎﺳﺗﺷﯾري طﺑﯾﺑك أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ ﻗﺑل ﺗﻠﻘﻲ اﻟﻌﻼج ﺑﮭذا اﻟدواء. ﻟﯾس ﻣﻌروﻓﺎ ﻣﺎ إذا ﻛﺎن أوﻛﺳﺑرﯾﺗﺎ ﯾﻧﺗﻘل إﻟﻰ ﻟﺑن اﻷم أو ﯾﺿر ﺑطﻔﻠك.</p><p>&nbsp;</p><p>و. اﻟﻘﯾﺎدة وﺗﺷﻐﯾل اﻵﻻت</p><p dir="RTL">ﻻ ﯾؤﺛر أوﻛﺳﺑرﯾﺗﺎ ﻋﻠﻰ اﻟﻘﯾﺎدة واﺳﺗﺧدام اﻵﻻت.</p><p>&nbsp;</p><p>ز. ﻣﻌﻠوﻣﺎت ﻣﮭﻣﺔ ﻋن ﺑﻌض ﻣﻛوﻧﺎت أوﻛﺳﺑرﯾﺗﺎ</p><p dir="RTL"><strong>أوﻛﺳﺑرﯾﺗﺎ</strong><strong> </strong><strong>ﯾﺣﺗوي ﻋﻠﻰ اﻟﺻودﯾوم</strong></p><p dir="RTL">ﯾﺣﺗوي&nbsp;ھذا اﻟدواء ﻋﻠﻰ أﻗل ﻣن ﻣﻠﻠﯾﻣول ﻣن اﻟﺻودﯾوم 23)&nbsp;ﻣﺟم(&nbsp;ﻟﻛل ﺟرﻋﺔ ﻣﻛوﻧﺔ ﻣن ﺛﻼﺛﺔ أﻗراص، أي أﻧﮫ ﯾﻌﺗﺑر &quot;ﺧﺎﻟ&nbsp;ﯾﺎ ﻣن اﻟﺻودﯾوم&quot;&nbsp;ﺑﺷﻛل&nbsp;أﺳﺎﺳﻲ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اﺳﺗﺧدم أوﻛﺳﺑرﯾﺗﺎ ﺗﻣﺎ ﻣﺎ ﻛﻣﺎ وﺻﻔﮫ ﻟك اﻟطﺑﯾب اﻟﻣﺧﺗص. ﻻ ﺗﻐﯾر ﺟرﻋﺔ أوﻛﺳﺑرﯾﺗﺎ أو ﺗﺗوﻗف ﻋن ﺗﻧﺎوﻟﮫ ﻣﺎ ﻟم ﯾﺧﺑرك ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ ﺑذﻟك.</p><p dir="RTL">اﺳﺗﺷر طﺑﯾﺑك أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ إذا ﻛﻧت ﻏﯾر ﻣﺗﺄﻛد.</p><p dir="RTL">&nbsp; ﺗﻧﺎول أوﻛﺳﺑرﯾﺗﺎ ﻣرة واﺣدة ﯾوﻣﯾﺎ.&nbsp;ﯾﺟب ﺑﻠﻊ ﻗرص أوﻛﺳﺑرﯾﺗﺎ ﻛﺎﻣ&nbsp;ﻼ.&nbsp;ﻻ ﺗﻛﺳر أو ﺗﺳﺣﻖ أو ﺗﻣﺿﻎ اﻷﻗراص.</p><p dir="RTL">&nbsp; ﺗﻧﺎول أوﻛﺳﺑرﯾﺗﺎ ﻣﻊ اﻟطﻌﺎم أو ﺑدوﻧﮫ.</p><p dir="RTL">&nbsp; ﯾﻣﻛن ﻟطﺑﯾﺑك أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ أن ﯾﻌدل ﺟرﻋﺗك إذا ﻟزم اﻷﻣر.</p><p dir="RTL">&nbsp; ﻛﻣﺎ ﯾﻣﻛن أن ﯾﺻف ﻟك طﺑﯾﺑك أو ھﯾدروﻛﺳﻲ ﯾورﯾﺎ أﺛﻧﺎء اﻟﻌﻼج ﺑﺄوﻛﺳﺑرﯾﺗﺎ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻣﺛل ﺟﻣﯾﻊ اﻷدوﯾﺔ، ﯾﻣﻛن أن ﯾﺗﺳﺑب أوﻛﺳﺑرﯾﺗﺎ ﻓﻲ أﻋراض ﺟﺎﻧﺑﯾﺔ، إﻻ أﻧﮭﺎ ﻻ ﺗظﮭر ﻋﻠﻰ ﺟﻣﯾﻊ اﻷﺷﺧﺎص.</p><p>&nbsp;</p><p dir="RTL"><strong>ﺗﻔﺎﻋﻼت</strong><strong> </strong><strong>ﺣﺳﺎﺳﯾﺔ ﺧطﯾرة (</strong><strong>ﻗد ﺗؤﺛر ﻓﻲ ﺷﺧص واﺣد ﻣن ﻛل </strong><strong>100</strong><strong> </strong><strong>ﺷﺧص</strong><strong>)</strong> اﺗﺻل ﺑطﺑﯾﺑك أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ أو اطﻠب اﻟﻣﺳﺎﻋدة اﻟطﺑﯾﺔ ﻋﻠﻰاﻟﻔور إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن واﺣد أو أﻛﺛر ﻣن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﺗﺎﻟﯾﺔ:</p><p dir="RTL">o طﻔﺢ ﺟﻠدي</p><p dir="RTL">o اﻟﺷرى</p><p dir="RTL">o ﺿﯾﻖ ﻓﻲ اﻟﺗﻧﻔس</p><p dir="RTL">o ﺗورم اﻟوﺟﮫ</p><p>&nbsp;</p><p>آﺛﺎر ﺟﺎﻧﺑﯾﺔ ﺷﺎﺋﻌﺔ ﺟ دا (ﻗد ﺗؤﺛر ﻓﻲ أﻛﺛر ﻣن ﺷﺧص ﻣن ﻛل 10 أﺷﺧﺎص)</p><p dir="RTL">o إﺳﮭﺎل</p><p dir="RTL">o أﻟم ﻓﻲ اﻟﺑطن</p><p dir="RTL">o ﻏﺛﯾﺎن</p><p dir="RTL">o ﺻداع</p><p dir="RTL">o طﻔﺢ ﺟﻠدي</p><p dir="RTL">o إرھﺎق</p><p dir="RTL">o اﻟﺣﻣﻰ</p><p>&nbsp;</p><p dir="RTL">&nbsp; أﺧﺑر طﺑﯾﺑك أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ أو اطﻠب اﻟﻣﺳﺎﻋدة اﻟطﺑﯾﺔ ﻋﻠﻰ اﻟﻔور إذا ظﮭرت ﻋﻠﯾك أي ﺗﻔﺎﻋﻼت ﺣﺳﺎﺳﯾﺔ ﺧطﯾرة.</p><p dir="RTL">&nbsp; ﻻ ﺗﺷﻣل ھذه اﻷﻋراض اﻟﻣذﻛورة ﺟﻣﯾﻊ اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﻣﺣﺗﻣﻠﺔ ﻷوﻛﺳﺑرﯾﺗﺎ.</p><p dir="RTL">&nbsp; اﺗﺻل ﺑطﺑﯾﺑك أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ ﻟﻠﺣﺻول ﻋﻠﻰ اﺳﺗﺷﺎرة طﺑﯾﺔ ﺣول اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ.</p><p dir="RTL">&nbsp; إذا أﺻﺑﺣت أي ﻣن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ ﺧطﯾرة، أو إذا ﻻﺣظت وﺟود أي آﺛﺎر ﺟﺎﻧﺑﯾﺔ ﺑﺧﻼف اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﻣذﻛورة ﻓﻲ ھذه اﻟﻧﺷرة، ﻓﯾﺟب</p><p dir="RTL">ﻋﻠﯾك أن ﺗﺧﺑر طﺑﯾﺑك أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ھـ</strong><strong>.</strong><strong> </strong><strong>ﻟﻺﺑﻼغ ﻋن أي آﺛﺎر ﺟﺎﻧﺑﯾﺔ</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp; </strong><strong>اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ</strong><strong>:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_1" o:spid="_x0000_s1029" style='position:absolute;
  margin-left:71.9pt;margin-top:6.7pt;width:282pt;height:72.25pt;z-index:-251657216;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordsize="35814,9175" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Graphic_x0020_2" o:spid="_x0000_s1030" style='position:absolute;
   width:35814;height:9175;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="3581400,917575" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m3442716,917448r-3304032,l108204,911352,68580,891540,36576,862584,12192,824484,1524,780288,,763524,,153924,7620,108204,27432,68580,56388,36576,94488,12192,155448,,3427476,r30480,3048l155448,3048,138684,4572,124968,7620r-15240,3048l96012,15240,82296,21336,70104,28956,59436,38100,48985,47244r-217,l47244,48768r190,l38100,59436,15240,96012,7924,123444r-304,l4572,138684r,641604l7620,794004r3048,15240l28956,848868r18478,21336l47244,870204r1524,1524l48985,871728r10451,9144l70104,890016r12192,7620l85039,897636r10973,6096l109728,908304r15240,3048l123444,911352r15240,3048l3457956,914400r-15240,3048xem3534156,48768l3521964,38100r1524,l3511296,28956r-12192,-7620l3485388,15240r-13716,-4572l3456432,7620r1524,l3442716,4572,3427476,3048r30480,l3500628,19812r35052,25908l3537204,47244r-3048,l3534156,48768xem47244,48768r1524,-1524l48056,48056r-812,712xem48056,48056r712,-812l48985,47244r-929,812xem3575304,124968l3560064,82296,3543300,59436r-9144,-12192l3537204,47244r9144,9144l3561588,80772r7620,13716l3573780,108204r4572,15240l3575304,123444r,1524xem47434,48768r-190,l48056,48056r-622,712xem7620,124968r,-1524l7924,123444r-304,1524xem3537204,871728r-3048,l3543300,859536r9144,-10668l3560064,836676r15240,-42672l3578352,763524r,-608076l3576828,138684r-1524,-15240l3578352,123444r3048,30480l3581400,763524r-7620,47244l3546348,862584r-9144,9144xem48768,871728r-1524,-1524l48056,870915r712,813xem48056,870915r-812,-711l47434,870204r622,711xem3503066,897636r-3962,l3511296,890016r12192,-9144l3521964,880872r12192,-10668l3534156,871728r3048,l3535680,873252r-10668,9144l3512820,891540r-9754,6096xem48985,871728r-217,l48056,870915r929,813xem85039,897636r-2743,l82296,896112r2743,1524xem3457956,914400r-15240,l3457956,911352r-1524,l3471672,908304r13716,-4572l3499104,896112r,1524l3503066,897636r-2438,1524l3486912,906780r-13716,4572l3457956,914400xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
   path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Textbox_x0020_3" o:spid="_x0000_s1031" type="#_x0000_t202"
   style='position:absolute;width:35814;height:9175;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=right dir=RTL style='margin-top:12.1pt;
      margin-right:.15in;margin-bottom:0in;margin-left:135.35pt;margin-bottom:
      .0001pt;text-align:left;text-indent:12.7pt;direction:rtl;unicode-bidi:
      embed'><span lang=AR-SA style='font-size:10.0pt'>اﻟﻣرﻛز<span
      style='letter-spacing:-.5pt'> </span>اﻟوطﻧﻲ<span style='letter-spacing:
      -.5pt'> </span>ﻟﻠﺗﯾﻘظ<span style='letter-spacing:-.5pt'> </span>واﻟﺳﻼﻣﺔ<span
      style='letter-spacing:-.5pt'> </span>اﻟدواﺋﯾﺔ </span><span dir=LTR></span><span
      dir=LTR style='font-size:10.0pt;font-family:Symbol;mso-bidi-font-family:
      Symbol'><span dir=LTR></span>·</span><span dir=RTL></span><span
      lang=AR-SA style='font-size:10.0pt;letter-spacing:2.0pt'><span dir=RTL></span><span
      style='mso-spacerun:yes'>  </span></span><span lang=AR-SA
      style='font-size:10.0pt'>ﻓﺎﻛس</span><span dir=LTR></span><span dir=LTR
      style='font-size:10.0pt'><span dir=LTR></span>:</span><span dir=RTL></span><span
      style='font-size:10.0pt'><span dir=RTL></span> </span><span dir=LTR></span><span
      dir=LTR style='font-size:10.0pt'><span dir=LTR></span>7398-210-1-966+<o:p></o:p></span></p>
      <p class=MsoNormal align=right dir=RTL style='margin-left:75.7pt;
      text-align:left;line-height:12.2pt;mso-line-height-rule:exactly;
      direction:rtl;unicode-bidi:embed'><span dir=LTR style='font-size:10.0pt;
      font-family:Symbol;mso-bidi-font-family:Symbol;letter-spacing:-.5pt'>·</span><span
      dir=RTL></span><span lang=AR-SA style='font-size:10.0pt;letter-spacing:
      3.35pt'><span dir=RTL></span><span style='mso-spacerun:yes'>  </span></span><span
      lang=AR-SA style='font-size:10.0pt'>اﻟﺑرﯾد<span style='letter-spacing:
      -.25pt'> </span>اﻹﻟﻛﺗروﻧﻲ</span><span dir=LTR></span><span dir=LTR
      style='font-size:10.0pt'><span dir=LTR></span>:</span><span dir=RTL></span><span
      style='font-size:10.0pt;letter-spacing:-.15pt'><span dir=RTL></span> </span><a
      href="mailto:npc.drug@sfda.gov.sa"><span dir=LTR style='font-size:10.0pt;
      color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
      dir=LTR style='font-size:10.0pt'><o:p></o:p></span></p>
      <p class=MsoNormal align=right dir=RTL style='margin-left:79.15pt;
      text-align:left;direction:rtl;unicode-bidi:embed'><span dir=LTR
      style='font-size:10.0pt;font-family:Symbol;mso-bidi-font-family:Symbol;
      letter-spacing:-.5pt'>·</span><span dir=RTL></span><span lang=AR-SA
      style='font-size:10.0pt;letter-spacing:3.35pt'><span dir=RTL></span><span
      style='mso-spacerun:yes'>  </span></span><span lang=AR-SA
      style='font-size:10.0pt'>اﻟﻣوﻗﻊ<span style='letter-spacing:-.2pt'> </span>اﻹﻟﻛﺗروﻧﻲ</span><span
      dir=LTR></span><span dir=LTR style='font-size:10.0pt'><span dir=LTR></span>:</span><span
      dir=RTL></span><span style='font-size:10.0pt;color:#0000FD;letter-spacing:
      -.2pt'><span dir=RTL></span> </span><a href="http://www.sfda.gov.sa/npc"><span
      dir=LTR style='font-size:10.0pt;color:#0000FD'>www.sfda.gov.sa/npc</span></a><span
      dir=LTR style='font-size:10.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p dir="RTL">اﻟﻣرﻛز اﻟوطﻧﻲ ﻟﻠﺗﯾﻘظ واﻟﺳﻼﻣﺔ اﻟدواﺋﯾﺔ &middot;&nbsp;</p><p dir="RTL">ﻓﺎﻛس: 7398-210-1-966+</p><p dir="RTL">&middot;&nbsp; اﻟﺑرﯾد اﻹﻟﻛﺗروﻧﻲ: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp; اﻟﻣوﻗﻊ اﻹﻟﻛﺗروﻧﻲ: www.sfda.gov.sa/npc</p><p dir="RTL"><strong>&nbsp; </strong><strong>اﻟدول اﻷﺧرى اﻷﻋﺿﺎء ﻓﻲ ﻣﺟﻠس اﻟﺗﻌﺎون ﻟدول اﻟﺧﻠﯾﺞ اﻟﻌرﺑﯾﺔ</strong><strong>:</strong></p><p dir="RTL">ﯾرﺟﻰ اﻻﺗﺻﺎل ﻋﻠﻰ اﻟﺟﮭﺔ اﻟﻣﺧﺗﺻﺔ.</p><p><br /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:282pt;height:37.1pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﯾﺣﻔظ ﺑﻌﯾ دا ﻋن ﻣﺗﻧﺎول اﻷطﻔﺎل.</p><p dir="RTL">&nbsp; اﺣﻔظ أوﻛﺳﺑرﯾﺗﺎ ﻓﻲ درﺟﺔ ﺣرارة ﻻ ﺗﺗﺟﺎوز 30 درﺟﺔ ﻣﺋوﯾﺔ.</p><p dir="RTL">&nbsp; ﯾﺄﺗﻲ أوﻛﺳﺑرﯾﺗﺎ ﻓﻲ ﻋﺑوة ﻣﻘﺎوﻣﺔ ﻟﻌﺑث اﻷطﻔﺎل.</p><p dir="RTL">&nbsp; ﺗﺣﺗوي اﻟزﺟﺎﺟﺔ ﻋﻠﻰ ﻣﺟﻔف وﻗطﻌﺔ ﻣن أﻟﯾﺎف اﻟﺑوﻟﯾﺳﺗر ﻟﻠﻣﺳﺎﻋدة ﻓﻲ اﻟﺣﻔﺎظ ﻋﻠﻰ دواﺋك ﺟﺎﻓﺎ )ﺣﻣﺎﯾﺗﮫ ﻣن اﻟرطوﺑﺔ.( ﻻ ﺗﺿﻊ زﺟﺎﺟﺔ</p><p dir="RTL">اﻟدواء ﻓﻲ ﻓﻣك.</p><p dir="RTL">&nbsp; ﻻ ﯾﺳﺗﻌﻣل أوﻛﺳﺑرﯾﺗﺎ ﺑﻌد اﻧﺗﮭﺎء ﺗﺎرﯾﺦ اﻟﺻﻼﺣﯾﺔ اﻟﻣوﺿﺢ ﻋﻠﻰ اﻟزﺟﺎﺟﺔ ﺑﻌد ﻛﻠﻣﺔ .&quot;EXP&quot;&nbsp;ﯾﺷﯾر ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ إﻟﻰ اﻟﯾوم اﻷﺧﯾر</p><p dir="RTL">ﻣن اﻟﺷﮭر.</p><p dir="RTL"><strong>&nbsp; </strong><strong>ﯾﻧﺑﻐﻲ ﻋدم اﻟﺗﺧﻠص ﻣن أي أدوﯾﺔ ﻓﻲ ﻣﯾﺎه اﻟﺻرف أو اﻟﻧﻔﺎﯾﺎت اﻟﻣﻧزﻟﯾﺔ</strong><strong>.</strong><strong> </strong><strong>اﺳﺄل اﻟﺻﯾدﻟﻲ ﻋن ﻛﯾﻔﯾﺔ اﻟﺗﺧﻠص ﻣن اﻷدوﯾﺔ اﻟﺗﻲ ﻟم ﺗﻌد ﺑﺣﺎﺟﺔ</strong></p><p dir="RTL"><strong>إﻟﯾﮭﺎ</strong><strong>.</strong><strong> </strong><strong>ﺗﺳﺎﻋد ھذه اﻟﺗداﺑﯾر ﻓﻲ ﺣﻣﺎﯾﺔ اﻟﺑﯾﺋﺔ</strong><strong>.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp; اﻟﻣﺎدة اﻟﻔﻌﺎﻟﺔ ھﻲ ﻓوﻛﺳﯾﻠوﺗور. ﯾﺣﺗوي ﻛل ﻗرص ﻋﻠﻰ 500 ﻣﺟم ﻓوﻛﺳﯾﻠوﺗور</p><p dir="RTL">&nbsp; اﻟﻣﻛوﻧﺎت اﻷﺧرى ھﻲ:</p><p dir="RTL">o ﺛﺎﻧﻲ أﻛﺳﯾد اﻟﺳﯾﻠﯾﻛون اﻟﻐروي</p><p dir="RTL">o ﻛروس ﻛﺎرﻣﯾﻠوز اﻟﺻودﯾوم</p><p dir="RTL">o ﺳﺗرات اﻟﻣﻐﻧﯾﺳﯾوم</p><p dir="RTL">o اﻟﺳﻠﯾﻠوز اﻟﺟرﯾزوﻓوﻟﻔﯾن o ﻛﺑرﯾﺗﺎت ﻟورﯾل اﻟﺻودﯾوم o ﺑوﻟﻲ إﯾﺛﯾﻠﯾن ﻏﻠﯾﻛول 3350</p><p dir="RTL">o ﺑوﻟﻲ ﻓﯾﻧﯾل اﻟﻛﺣول</p><p dir="RTL">o اﻟﺗﻠك</p><p dir="RTL">o ﺛﺎﻧﻲ أﻛﺳﯾد اﻟﺗﯾﺗﺎﻧﯾوم</p><p dir="RTL">o أﻛﺳﯾد اﻟﺣدﯾد اﻷﺻﻔر (E172)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أﻗراص أوﻛﺳﺑرﯾﺗﺎ اﻟﻣﻐﻠﻔﺔ ﻟوﻧﮭﺎ ﻣﺎ ﺑﯾن اﻷﺻﻔر اﻟﻔﺎﺗﺢ واﻷﺻﻔر، وﺑﯾﺿﺎوﯾﺔ اﻟﺷﻛل وﻣﺧﺗوم ﻋﻠﻰ أﺣد ﺟﺎﻧﺑﯾﮭﺎ 500 GBT</p><p dir="RTL">&nbsp;</p><p dir="RTL">دواء أوﻛﺳﺑرﯾﺗﺎ ﻣﻌﺑﺄ ﻓﻲ زﺟﺎﺟﺔ ﺑﻼﺳﺗﯾﻛﯾﺔ ﻣﻊ ﻏطﺎء ﻣﻘﺎوم ﻟﻸطﻔﺎل. ﺗﺣﺗوي ﻛل زﺟﺎﺟﺔ ﻋﻠﻰ 90 ﻗرصا مغلفا. تحتوي الزجاجة ايضا على قطعة من&nbsp;أﻟﯾﺎف اﻟﺑوﻟﯾﺳﺗر وﻛﯾس ﺻﻐﯾر ﻣن ﻣﺟﻔف ھﻼم اﻟﺳﯾﻠﯾﻛﺎ ﻟﻠﻣﺳﺎﻋدة ﻓﻲ اﻟﺣﻔﺎظ ﻋﻠﻰ دواﺋك ﺟﺎﻓﺎ. ﻻ ﺗﺿﻊ ﻛﯾس اﻟﻣﺟﻔف ﻓﻲ ﻓﻣك أو ﺗزﯾﻠﮫ ﻣن اﻟزﺟﺎﺟﺔ.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اﻟﺷرﻛﺔ اﻟﻣﺎﻟﻛﺔ ﻟرﺧﺻﺔ اﻟﺗﺳوﯾﻖ</p><p>Global Blood Therapeutics, Inc. 181 Oyster Point Boulevard, Suite 300 South San Francisco, CA 94080</p><p dir="RTL">اﻟوﻻﯾﺎت اﻟﻣﺗﺣدة اﻷﻣرﯾﻛﯾﺔ</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp; ﺟﮭﺔ اﻟﺗﺻﻧﯾﻊ</p><p>Patheon, Inc. 111 Consumers Drive Whitby, Ontario L1N 5Z5</p><p dir="RTL">ﻛﻧدا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            -
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OXBRYTA 500 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OXBRYTA 500 mg film-coated tablets.
Each film-coated tablet contains 500 mg of voxelotor. For the full list of excipients, see Section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet)
Light yellow to yellow, oval shaped, biconvex, film-coated tablet, debossed with “GBT 500” on one side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older. OXBRYTA can be administered alone or in combination with hydroxyurea (HU).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dosage of OXBRYTA is 1500 mg taken orally once daily with or without food. If a dose is missed, dosing should be continued on the day following the missed dose.</p><p>OXBRYTA may be given with or without hydroxyurea (HU).</p><p>1.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paediatric use</p><p>The safety and effectiveness of voxelotor for sickle cell disease have been established in paediatric patients aged 12 years and older in Study GBT440-031 (HOPE). The HOPE trial enrolled a total of 29 paediatric patients aged 12 to &lt; 18 years, in which 14 paediatric patients received voxelotor 1500 mg once daily and 15 paediatric patients received voxelotor 900 mg once daily.</p><p>Pharmacokinetics, safety and efficacy in paediatric patients 12 years to &lt; 18 years were similar to that observed in adults<em>.</em></p><p>&nbsp;</p><p>The adverse reactions observed in paediatric patients 12 to &lt; 18 years treated with voxelotor were similar in type and frequency to those observed in adults.</p><p>1.1.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geriatric use</p><p>Clinical studies of voxelotor did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p><p><em>Renal impairment</em></p><p>No clinically significant differences in the pharmacokinetics of voxelotor were observed in patients with mild to severe renal impairment. OXBRYTA has not been evaluated in patients with end stage renal disease requiring dialysis (see Section 5.2). No dose modification is recommended.</p><p><em>Hepatic impairment</em></p><p>Severe hepatic impairment increases voxelotor exposures. The recommended dosage of OXBRYTA in patients with severe hepatic impairment (Child Pugh C) is 1000 mg taken once daily with or without food. No dosage adjustment of OXBRYTA is required for patients with mild or moderate hepatic impairment (see Section 5.2).</p><p><em>Concomitant moderate or strong inducers, strong inhibitors of CYP3A4, or Fluconazole</em></p><p>Avoid concomitant use of strong or moderate CYP3A4 inducers, strong CYP3A4 inhibitors, or fluconazole with OXBRYTA (see Section 4.5 and Section 5.2). If concomitant use of strong or moderate CYP3A4 inducers, strong CYP3A4 inhibitors, or fluconazole is unavoidable, adjust the OXBRYTA dosage as recommended below.</p><p>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OXBRYTA recommended dosage for concomitant medications</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Concomitant</strong><strong> </strong><strong>medication</strong></p></td><td style="vertical-align:top"><p><strong>Recommended OXBRYTA dosage</strong></p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP3A4 inhibitors or fluconazole</p></td><td style="vertical-align:top"><p>1000 mg once daily</p></td></tr><tr><td style="vertical-align:top"><p>Strong or moderate CYP3A4 inducers</p></td><td style="vertical-align:top"><p>2500 mg once daily</p></td></tr></tbody></table><p><u>Method of administration</u></p><p>OXBRYTA is for oral use. OXBRYTA tablets should be swallowed whole. The film-coated tablets should not be cut, crushed or chewed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Voxelotor is contraindicated in patients with a history of serious drug hypersensitivity reaction to voxelotor or excipients listed in Section 6.1. (See Special warnings and precautions for use [Section 4.4]).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions</p><p>Serious hypersensitivity reactions have been observed in &lt; 1% of patients treated with voxelotor in clinical trials. Clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia.</p><p>If hypersensitivity reactions occur, discontinue voxelotor and administer appropriate medical therapy Do not reinitiate voxelotor in patients who experience these symptoms with</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of other drugs on voxelotor</p><p><em>Strong CYP3A4 inhibitors or Fluconazole</em></p><p>Co-administration of strong CYP3A4 inhibitors or fluconazole may increase voxelotor plasma concentrations and may lead to increased toxicity. Avoid co-administration of voxelotor with strong CYP3A4 inhibitors or fluconazole and replace these drugs with alternative drugs when possible.</p><p>Decrease the voxelotor dosage when co-administration with a strong CYP3A4 inhibitor or fluconazole is unavoidable.</p><p><em>Strong or moderate CYP3A4 inducers</em></p><p>Co-administration of strong or moderate CYP3A4 inducers may decrease voxelotor plasma concentrations and may lead to reduced efficacy.</p><p>&nbsp;</p><p>Effect of voxelotor on other drugs</p><p>Voxelotor increased the systemic exposure of midazolam (a sensitive CYP3A4 substrate). Avoid co-administration of voxelotor with sensitive CYP3A4 substrates with a narrow therapeutic index. If concomitant use is unavoidable, consider dose reduction of the sensitive CYP3A4 substrate(s).</p><p>Drug interaction studies</p><p><em>Clinical studies and model-informed approaches</em></p><p><u>Effect of strong CYP3A4 inhibitors on voxelotor</u>: concomitant use of OXBRYTA with ketoconazole is predicted to increase voxelotor AUC in patients by 42% to 83%.</p><p><u>Effect of strong or moderate CYP3A4 inducers on voxelotor</u>: concomitant use of OXBRYTA with rifampin (a strong CYP3A4 inducer) is predicted to decrease voxelotor AUC in patients by up to 77%, and efavirenz (a moderate CYP3A4 inducer) is predicted to decrease voxelotor AUC in patients by up to 60%.</p><p>&nbsp;</p><p><u>Effect of Fluconazole on voxelotor</u>: concomitant use of OXBRYTA with fluconazole,</p><p>a moderate CYP3A4 inhibitor, a moderate CYP2C9 inhibitor and a strong CYP2C19 inhibitor, is predicted to increase voxelotor AUC in patients by 40% to 116%.</p><p><u>Effect of acid reducing agents on voxelotor</u>: co-administration of omeprazole (proton pump inhibitor) with OXBRYTA did not alter voxelotor exposure.</p><p><u>Effect of voxelotor on CYP450 enzymes</u>: in vivo voxelotor inhibits CYP3A4, but not CYP1A2, CYP2C9, CYP2C19, CYP2C8, or CYP2D6. The observed exposure increase of the CYP3A4 substrate midazolam in healthy subjects was 1.6-fold and the predicted increase in patients after multiple dosing is 2-fold.</p><p><u>Effect of voxelotor on P-gp</u>: concomitant use of Oxbyrta with digoxin (a P-gp substrate) did not alter digoxin to a clinically relevant extent.</p><p><em>In vitro studies</em></p><p><u>CYP enzymes</u>: voxelotor is a reversible and time-dependent inhibitor as well as an inducer of CYP2B6.</p><p><u>Transporter systems</u>: voxelotor is not an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, OCT2, OAT1, OAT3, MATE1, MATE2-K, or BSEP. Voxelotor is not a substrate of P-gp, BCRP, OATP1A2, OATP1B1, OATP1B3, or BSEP.</p><p>Laboratory test interference</p><p>OXBRYTA administration may interfere with measurement of Hb subtypes (HbA, HbS, and HbF) by HPLC (see Section 4.4). If precise quantitation of Hb species is required, chromatography should be performed when the patient is not receiving OXBRYTA therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility</p><p><u>Risk summary</u></p><p>No human data are available on the effect of voxelotor on fertility. <u>Data</u></p><p><em>Animal Data</em></p><p>In the fertility study in rats, there were effects on sperm motility and morphology at the highest dose of 250 mg/kg/day, but there were no functional effects on male or female fertility at any dose.</p><p>&nbsp;</p><p>Pregnancy</p><p><u>Risk summary</u></p><p>There are no available data on voxelotor use in pregnant women to evaluate the drug associated risk of major birth defects, miscarriage or adverse maternal or foetal outcomes. In animal reproduction studies, oral administration of voxelotor to pregnant rats and rabbits during</p><p>&nbsp;</p><p>organogenesis at exposures up to 2.8-times (rats) and 0.3-times (rabbits) the exposure at the maximum recommended human dose resulted in no adverse developmental effects<em>.</em></p><p><u>Data</u></p><p><em>Animal data</em></p><p>In embryo-foetal development studies, voxelotor was administered orally to pregnant rats at 15, 50, and 250 mg/kg/day (gestation days 7 through 17) and rabbits at 25, 75, and</p><p>150 mg/kg/day (gestation days 7 through 19) through organogenesis. Maternal toxicity was observed at the highest dose levels in these studies equivalent to 2.8-times (rats) and 0.3-times (rabbits) the exposures in patients receiving voxelotor at the recommended daily dose. There was no evidence of adverse developmental outcomes in rats or rabbits.</p><p>In a pre- and postnatal development study, voxelotor was administered orally to pregnant rats at 15, 50 and 250 mg/kg/day (gestation day 6 through lactation day 20). Maternal gestational body weights were decreased at 250 mg/kg/day, which continued to the end of lactation. The findings in offspring included reduced survival and reduced body weights throughout lactation, weaning and maturation. The effects in offspring were observed at the maternal dose of 250 mg/kg/day with an exposure approximately 2.8-times the exposure in patients at the recommended dose.</p><p>&nbsp;</p><p>Lactation</p><p>There are no data on the presence of voxelotor in human milk, the effects on the breastfed child, or the effects on milk production. Voxelotor was detected in milk in lactating rats. Plasma concentrations of voxelotor in pregnant rats were higher than the concentration in milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk.</p><p>The concentration of voxelotor in animal milk does not necessarily predict the concentration of drug in human milk. Because of the potential for serious adverse reactions in the breastfed child, including changes in the hematopoietic system, advise patients that breastfeeding is not recommended during treatment with voxelotor, and for at least 2 weeks after the last dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of voxelotor on the ability to drive and use machines have been performed. Safety pharmacology studies did not identify any adverse or drug related effects of voxelotor on the CNS.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions</p><p>Adverse reactions (&ge; 10%) in patients receiving OXBRYTA 1500 mg in HOPE with a difference of &gt; 3% compared to placebo are summarized in Table 1.</p><p>Adverse reactions for OXBRYTA are listed by MedDRA System Organ Class and Preferred Term (see <strong>Error! Reference source not found. </strong>ADR). Within each System Organ Class, adverse reactions are listed under frequency categories of: Very common (&ge; 1/10); Common (&ge; 1/100 to &lt; 1/10); Uncommon (&ge; 1/1,000 to &lt; 1/100); Rare (&ge; 1/10,000 to &lt; 1/1,000); Very</p><p>&nbsp;</p><p>Rare (&lt; 1/10,000); Not known (cannot be estimated from available clinical trial data). Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.</p><p>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ADR: Adverse Reactions in patients receiving voxelotor in HOPE</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions<sup>a</sup></strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Abdominal pain (grouped PTs)<sup>b</sup> Nausea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue Pyrexia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Drug hypersensitivity</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rash<sup>c</sup></p></td></tr></tbody></table><p>a Adverse reactions were Grades 1 or 2 except for Grade 3 diarrhoea (1), nausea (1), rash (1), and rash generalized (3).</p><p>b Abdominal pain (grouped PTs) included the following PTs: abdominal pain and upper abdominal pain.</p><p>c Rash (grouped PTs) includes the following PTs: rash, urticaria, generalized rash, maculo-papular rash, pruritic rash, papular rash, erythematous rash, and vesicular rash.</p><p>&nbsp;</p><p>&nbsp;</p><p>Clinical trials experience</p><p>The safety of voxelotor was evaluated in Study GBT440-031 (HOPE), a randomized, double- blind, placebo-controlled phase 3 trial, and based upon 88 patients who received voxelotor</p><p>1500 mg. and 91 patients who received placebo orally once daily. Seventy-four patients received voxelotor 1500 mg once daily for &ge; 24 weeks and 65 patients for &ge; 48 weeks.</p><p>Serious adverse events considered related by Investigators occurred in 3% (3/88) of patients receiving voxelotor 1500 mg, which included headache, drug hypersensitivity, and pulmonary embolism occurring in 1 patient each. Permanent discontinuation due to an adverse reaction (Grades 1&ndash;4) occurred in 5% (4/88) of patients who received voxelotor 1500 mg.</p><p>Dosage modifications (dose reduction or dosing interruption) due to an adverse reaction occurred in 41% (36/88) of patients who received voxelotor. Most frequent adverse reactions requiring dosage interruption occurring in more than one patient who received voxelotor 1500 mg included diarrhoea, headache, rash, and vomiting.</p><p>The safety profile observed in paediatric patients 12 to &lt; 18 years of age treated with voxelotor was similar to that seen in adult patients.</p><p>[Description of selected ADRs]</p><p>&nbsp;</p><p><u>Diarrhoea</u></p><p>In the pivotal Phase 3 study, diarrhoea and nausea showed a dose-depended effect. Diarrhoea was the most commonly and was reported in 20.5%, 17.4%, and 9.9% of subjects in the voxelotor 1500 mg, 900 mg, and placebo groups respectively. The single PT of diarrhoea was examined in an exposure-safety analysis that included 274 patients from the pivotal trial that had available plasma PK exposure estimates.</p><p>SAEs of diarrhoea were infrequent and did not result in study drug discontinuation. There were no SAEs of diarrhoea reported in the 1500 mg group; 1 SAE of diarrhoea was reported in the 900 mg group. The single episode of diarrhoea occurred on Study Days 112 through 118, was Grade 3, and was assessed by the Investigator as not related to study drug. Treatment with study drug was interrupted and the event resolved with medication. Other events of diarrhoea were non-serious, Grade 1 or 2 in severity, self-limiting, and were clinically manageable without the need for dose interruption or reduction or treatment discontinuation. There were no events of bloody diarrhoea or fatty stools or associated complications such as dehydration reported.</p><p><u>Drug hypersensitivity</u></p><p>In the pivotal Phase 3 study, 1 subject across all treatment groups had a TEAE of drug hypersensitivity. The subject in the 1500 mg treatment group had multiple events of drug hypersensitivity that led to study drug discontinuation. Treatment exposure to time of event onset occurred on Study Day 40. Observed symptoms included generalized morbilliform rash, urticaria, mild shortness of breath, mild facial swelling, pyrexia, headache, and diarrhoea.</p><p>Elevated eosinophils were noted. Symptoms abated after study drug was withheld; and recurrence observed after reintroduction of study drug despite 2 dose reductions. Event resolved with medication. The event was confounded with the subject&rsquo;s concomitant use of platelet-rich plasma for hair growth.</p><p><u>Rash</u></p><p>In the pivotal Phase 3 study, rash was reported in 13.6%, 10.9%, and 9.9% of subject in the voxelotor 1500 mg, 900 mg, and placebo groups, respectively. Serious TEAEs of rash were infrequent and rarely resulted in study drug discontinuation. The majority of rash events were similar in appearance (consistent with typical maculopapular drug eruptions) and distribution, were not associated with extradermal symptoms, and were clinically manageable with or without treatment including oral antihistamines or topical corticosteroids. Exposure-response analysis did not reveal a statistically significant dose- or exposure-response relationship. There were no events of Stevens-Johnson syndrome reported.</p><p>&nbsp;</p><p>Post-marketing Experience</p><p>To report any side effect(s):</p><p><!--[if gte vml 1]><o:wrapblock><v:group id="Group_x0020_7" o:spid="_x0000_s1029"
  style='position:absolute;left:0;text-align:left;margin-left:95.9pt;
  margin-top:13.3pt;width:263.55pt;height:72.25pt;z-index:-15728640;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordsize="33470,9175" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Graphic_x0020_8" o:spid="_x0000_s1030" style='position:absolute;
   width:33470;height:9175;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="3347085,917575" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m3192780,917448r-3037332,l123444,914400,80772,899160,45720,871728,19812,836676,1524,778764,,763524,,153924,7620,108204,19812,80772,27432,67056,36576,56388,45720,44196,56388,35052,68580,25908,80772,18288,108204,6096,138684,,3209544,r15240,3048l138684,3048,124968,6096,82296,21336,47244,47244r1524,l38100,57912,30099,68580r-1143,l21336,82296,15240,94488r-4572,13716l4572,138684r,640080l15240,821436r22860,38100l48768,870204r-1524,l59436,879348r10668,9144l82296,896112r13716,6096l109728,906780r15240,4572l123444,911352r32004,3048l3224784,914400r-32004,3048xem3224784,914400r-32004,l3223260,911352r15240,-4572l3278124,888492r32004,-28956l3337560,807720r6096,-28956l3343656,138684,3331464,94488,3310128,57912,3278124,28956,3238500,9144,3208020,3048r16764,l3265932,18288r36576,25908l3311652,56388r9144,10668l3340608,108204r6096,28956l3346704,778764r-18288,57912l3302508,871728r-36576,27432l3238500,909828r-13716,4572xem28956,70104r,-1524l30099,68580r-1143,1524xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
   path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Textbox_x0020_9" o:spid="_x0000_s1031" type="#_x0000_t202"
   style='position:absolute;width:33470;height:9175;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:.45pt'><b style='mso-bidi-font-weight:
      normal'><span style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-hansi-font-family:"Times New Roman";
      mso-bidi-font-family:"Times New Roman"'><o:p>&nbsp;</o:p></span></b></p>
      <p class=MsoNormal style='margin-left:16.95pt;text-indent:-6.05pt;
      mso-list:l1 level1 lfo1;tab-stops:16.95pt'><![if !supportLists]><span
      style='font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
      Arial;mso-font-width:99%'><span style='mso-list:Ignore'>-<span
      style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
      dir=LTR></span><span style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-hansi-font-family:"Times New Roman";
      mso-bidi-font-family:"Times New Roman"'>National<span style='letter-spacing:
      -.55pt'> </span>Pharmacovigilance<span style='letter-spacing:-.5pt'> </span>Center<span
      style='letter-spacing:-.5pt'> </span><span style='letter-spacing:-.1pt'>(NPC)</span><o:p></o:p></span></p>
      <p class=MsoNormal style='margin-top:.1pt;margin-right:0in;margin-bottom:
      0in;margin-left:46.9pt;margin-bottom:.0001pt;text-indent:-.25in;
      line-height:12.25pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;
      tab-stops:46.9pt'><![if !supportLists]><span style='font-size:10.0pt;
      font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
      Symbol;mso-font-width:99%'><span style='mso-list:Ignore'>·<span
      style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </span></span></span><![endif]><span dir=LTR></span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
      letter-spacing:-.1pt'>Fax:</span><span style='font-size:10.0pt;
      mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-hansi-font-family:
      "Times New Roman";mso-bidi-font-family:"Times New Roman";letter-spacing:
      .6pt'> </span><span style='font-size:10.0pt;mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-hansi-font-family:"Times New Roman";
      mso-bidi-font-family:"Times New Roman";letter-spacing:-.1pt'>+966-1-210-</span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
      letter-spacing:-.2pt'>7398</span><span style='font-size:10.0pt;
      mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-hansi-font-family:
      "Times New Roman";mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
      <p class=MsoNormal style='margin-left:46.9pt;text-indent:-.25in;
      line-height:12.2pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;
      tab-stops:46.9pt'><![if !supportLists]><span style='font-size:10.0pt;
      font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
      Symbol;mso-font-width:99%'><span style='mso-list:Ignore'>·<span
      style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </span></span></span><![endif]><span dir=LTR></span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman"'>E-mail:<span
      style='letter-spacing:-.25pt'> </span></span><a
      href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:10.0pt;
      mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-hansi-font-family:
      "Times New Roman";mso-bidi-font-family:"Times New Roman";color:windowtext;
      letter-spacing:-.1pt;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
      <p class=MsoNormal style='margin-left:46.9pt;text-indent:-.25in;
      line-height:12.2pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo1;
      tab-stops:46.9pt'><![if !supportLists]><span style='font-size:10.0pt;
      font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
      Symbol;mso-font-width:99%'><span style='mso-list:Ignore'>·<span
      style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </span></span></span><![endif]><span dir=LTR></span><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman"'>Website:<span
      style='letter-spacing:-.45pt'> </span></span><a
      href="http://www.sfda.gov.sa/npc"><span style='font-size:10.0pt;
      mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-hansi-font-family:
      "Times New Roman";mso-bidi-font-family:"Times New Roman";color:#0000FD;
      letter-spacing:-.1pt'>www.sfda.gov.sa/npc</span></a><span
      style='font-size:10.0pt;mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman"'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:353.936px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:352.064px"><p>-&nbsp; National Pharmacovigilance Center (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-1-210-7398</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br /><strong>Saudi Arabia:</strong></p><p><strong>Other GCC States:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_10" o:spid="_x0000_s1026" style='position:absolute;
  margin-left:95.9pt;margin-top:3.55pt;width:263.55pt;height:31pt;z-index:-15728128;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' coordsize="33470,3937" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAPpHXb6cGAADRKQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWttu2zgQfV9g/0HQe2pJ1DWoU7Td
bbBAkQZJin1mZDoWVpa0Eu04/fo9vNmyW4tO6nRfjAAxLY1Gw8Mzh8OB375bzUtnydquqKux67/x
XIdVeT0pqoex+/Xu01nqOh2n1YSWdcXG7hPr3HcXv//2lp4/tLSZFbkDD1V3TsfujPPmfDTq8hmb
0+5N3bAK96Z1O6ccX9uH0aSlj/A8L0eB58WjOS0q92Lj6g/KqbNoixe4Kuv8Hzb5SKsl7eCyzM/7
V3SMZf7znul5tbxsm9vmuhWR51fL69YpJmMXyFV0Dojckb6hzfB1tPPUw8bBatrOhX09nTorrEDg
J0EWuc6TGGcJ8SLlj624k8OAkDDxUhjksCAZSTxPv3D2xeIin/057ARhqnAw6IUohyLGPTP311O/
bOtF4+D7DgTiYenlM5apU4AAuUsDwy/FB9ECOhPjCzHpGgXI9zzwfUOES50guGLwEOaGD+bRTlNp
hwlbYVpWf71wIOSi45eslpyiy88dl69+mJgRnZlRvqrMsGU5d8qxW7oOH7vcddqx27rO/di9V6E3
lIvnxJzF0HnsEXG25qG4Pa+X7K6WhlwQmgRpEsRQEUVXPwuERwS8MSyr/gOxl8Vq7mD3xtwYmc9G
eo+QDsbYj/Ea5dsYmU9lHCZBGOpAPB/DQWPfD3XUaYKQBo2JF6Y6jDSIgmHPfWPfU+kLPEys5lPF
7GepH6iYE0LwkqGYIR6AVyIdhwGxx6xswyjDVAcdizlJvyRLI7OCJlLzqSPe2JIkGo5BYxbEviVY
ZRhHETnw5ZiSxaVv4lQcGpz+ehH8NEiHoeqRDKQYRHVD3uFlJUFGSKwWwGqZhSZ7rK8PU+1UMHIw
0jBNdAqL7Bw0FbDqZZVJMYRrGCWKrvYlWJsSOwNljJKtYRhakrEXbhwkSLWheP0Yaqbzy2ocBKlZ
icRPLYlAUA/pDEuyMBmGOAxijRtJw8OXjth1rK+9VoUkxPOy9GBB7bOYZFax3rtvGLXJy7pjarXE
lvSSrQlZlWQ/WNB9WxMhmATyXymslQEwzzwDUORFgSV5sZXFnvZu12TsfIEPOTxQlmFOYrBQmQeB
RUj75nYtBS4R0QqBoCzKCxDXKmXVky3a2Mje92wVNfAXlbTSKikvQ6lPiJ8kuiDwPVulATziVG/F
9i0D1mnoq6U5xJrEHhAWCxmkmU1Y+izJYosaYtUjX0OCAWIaxiSMEy1bh3BkY43MsJUGW/RG6ljK
NXj8cS4fTy72qP8+sXjezrLZNWPft5QYewI53kz3Kvu+uW6L9SE7RxQZLUojUQUM88yPA1OA2rfH
vhiRA7Ze2G9E3Qr+8/eAYV6aVVPFs6CxSW6UfNYavqccxH4+6MvSQeYbzSOp9ajSl0hywDGoJ78H
lCZ7OWkA/K4ewJlqfWzFuH8w7uqymHwqylJUDV37cP+xbJ0lxQkY57HNkaxnBgfmnM5Xt/Lwz1cf
6smT8HCPT3SB0EbjX/BvWtY4H+dl0bjOrG6/7V57RF9g7Hb/LmjLXKf8q+pk94ibQWsG92bQ8vJj
LaKT3bKm7fjd6m/aNo4Y4sCO9sBVfTujDZMG5twvEFjbikCr+v2C19NCNAVwU8UtbpQdv+VPpain
8Iz4x6rJNW3pDeZVUtEMZNXZ11udp7DA4xsAFh27bW7QRFB+FUISMuFqoFeC8kU1ze4whft65agK
XPbVRH/EEe8QbTH94mr5Ol0TAZPommhART/kR0iqxoqcmGr//e9ceMaKCjjntP0MNHHcjtFCxLcb
Q6quyT+wqVqu/Jp3Kh2ySLYf5Yx7999PZSsIz6wtTW2La/IuHtF9LdknbXd45HTfEIdINUm26RSI
m25USXlROfypYVOao6H6vi0oOlMNrVDxI97A+4BCOcSn+cMhpCl4PvtE50UpGk24kM9o2zFkh4wM
hKY9l3fFnHXOFXt0buo5rbacB3COtiteEOEFKCN3nPso0Xed592rOQeQAE+gxC/OZNrJ5FOoisv7
oXWwGGP3jJxA3qbH9yvYB9l5Hsgn/vYzbxja65LRjj0PX03iIDopxZbGDSN9IvFRFb6vD3ldcZrz
F7H4JMXWzbQP9YnFr8ZiPjvp8LrCPG45eGLwLymGW1ayJa1OQnyisTwmHjeJ0YL4NWe6vJ43jLMT
jzcH/uOu5E/IsT574AdNp1Pe4ac8uuBoexb86c1Ojbynp6h6QWgGHYDycanxql0h8G4zYdmzeU7b
FE/r392Ndn7MKF3pH1+KX0z2v1/8BwAA//8DAFBLAwQUAAYACAAAACEA4VE3H88GAADmGwAAGgAA
AGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FnNb9xEFL8j8T+MfG+z381G3VTZzW4Dbdoo2Rb1
OGvP2tOMPdbMbNK9ofaIhIQoiAOVuHFAQKVW4lL+mkARFKn/Am9mbK8n65C0jaCC5pC1n3/zvt+b
r8tX7sUMHRAhKU96Xv1izUMk8XlAk7Dn3RqPLqx6SCqcBJjxhPS8OZHelfX337uM13xG0wnHIhhH
JCYIGCVyDfe8SKl0bWVF+kDG8iJPSQLfplzEWMGrCFcCgQ9BQMxWGrVaZyXGNPHWgaPSjIYM/iVK
aoLPxJ5mQ1CCY5B+czqlPjHYYL+uEXIuB0ygA8x6HvAM+OGY3FMeYlgq+NDzaubPW1m/vILXskFM
nTC2NG5k/rJx2YBgv2FkinBSCK2PWt1LmwV/A2BqGTccDgfDesHPALDvg6VWlzLP1mi13s95lkD2
cZn3oNautVx8iX9zSeduv99vdzNdLFMDso+tJfxqrdPaaDh4A7L49hK+1d8YDDoO3oAsvrOEH13q
dlou3oAiRpP9JbQO6GiUcS8gU862KuGrAF+tZfAFCrKhyC4tYsoTdVKuxfguFyMAaCDDiiZIzVMy
xT7k5ADHE0GxFoDXCC59sSRfLpG0LCR9QVPV8z5MceKVIC+fff/y2RN0dP/p0f2fjh48OLr/o2Xk
jNrCSVge9eLbz/589DH648k3Lx5+UY2XZfyvP3zyy8+fVwOhfBbmPf/y8W9PHz//6tPfv3tYAd8Q
eFKGj2lMJLpBDtEuj8Ew4xVXczIRrzZiHGFaHrGRhBInWEup4D9UkYO+Mccsi46jR5+4HrwtoH1U
Aa/O7joK70VipmiF5GtR7AC3OWd9Liq9cE3LKrl5PEvCauFiVsbtYnxQJXuAEye+w1kKfTNPS8fw
QUQcNXcYThQOSUIU0t/4PiEV1t2h1PHrNvUFl3yq0B2K+phWumRMJ042LQZt0RjiMq+yGeLt+Gb7
NupzVmX1JjlwkVAVmFUoPybMceNVPFM4rmI5xjErO/w6VlGVkntz4ZdxQ6kg0iFhHA0DImXVmJsC
7C0F/RqGjlUZ9m02j12kUHS/iud1zHkZucn3BxGO0yrsHk2iMvYDuQ8pitEOV1Xwbe5WiH6HOODk
xHDfpsQJ9+nd4BYNHZUWCaK/zISOJbRqpwPHNPm7dswo9GObA+fXjqEBPv/6UUVmva2NeAPmpKpK
2DrWfk/CHW+6Ay4C+vb33E08S3YIpPnyxPOu5b5rud5/vuWeVM9nbbSL3gptV68b7KLYLJHjE1fI
U8rYnpozcl2aRbKEeSIYAVGPMztBUuyY0gges77u4EKBzRgkuPqIqmgvwikssOueZhLKjHUoUcol
bOwMuZK3xsMiXdltYVtvGGw/kFht88CSm5qc7wsKNma2Cc3mMxfU1AzOKqx5KWMKZr+OsLpW6szS
6kY10+ocaYXJEMNl04BYeBMWIAiWLeDlDuzFtWjYmGBGAu13O/fmYTFROM8QyQgHJIuRtns5RnUT
pDxXzEkA5E5FjPQm7xSvlaR1Nds3kHaWIJXFtU4Ql0fvTaKUZ/AiSrpuj5UjS8rFyRJ02PO67Ubb
Qz5Oe94U9rTwGKcQdanXfJiFcBrkK2HT/tRiNlW+iGY3N8wtgjocU1i/Lxns9IFUSLWJZWRTw3zK
UoAlWpLVv9EGt56XATbTX0OL5iokw7+mBfjRDS2ZTomvysEuUbTv7GvWSvlMEbEXBYdowmZiF0P4
daqCPQGVcDRhOoJ+gXM07W3zyW3OWdGVT68MztIxSyOctVtdonklW7ip40IH81ZSD2yr1N0Y9+qm
mJI/J1PKafw/M0XPJ3BS0Ax0BHw4lBUY6XrteVyoiEMXSiPqjwQsHEzvgGyBs1j4DEkFJ8jmV5AD
/WtrzvIwZQ0bPrVLQyQozEcqEoTsQFsy2XcKs3o2d1mWLGNkMqqkrkyt2hNyQNhY98COnts9FEGq
m26StQGDO55/7ntWQZNQL3LK9eb0kGLutTXwT698bDGDUW4fNgua3P+FihWzqh1vhudzb9kQ/WGx
zGrlVQHCSlNBNyv711ThFada27GWLG60c+UgissWA7FYEKVw3oP0P5j/qPCZvW3QE+qY70JvRXDR
oJlB2kBWX7ALD6QbpCVOYOFkiTaZNCvr2mzppL2WT9bnvNIt5B5zttbsLPF+RWcXizNXnFOL5+ns
zMOOry3tRFdDZI+XKJCm+UbGBKbq1mkbp2gS1nse3PxAoO/BE9wdeUBraFpD0+AJLoRgsWRvcXpe
9pBT4LulFJhmTmnmmFZOaeWUdk6BxVl2X5JTOtCp9BUHXLHpHw/ltxmwgstuP/Km6lzNrf8FAAD/
/wMAUEsDBBQABgAIAAAAIQCcZkZBuwAAACQBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxz
L2RyYXdpbmcxLnhtbC5yZWxzhI/NCsIwEITvgu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB
8LIws+w3s037sjN5YkyTdxxqWgFBp7yenOFw6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigu
cRhzDifGkhrRykR9QFc2g49W5iKjYUGquzTI9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpY
dPlHBMulFxagjAYzB0pXZ501LV2BiYZ9/SbeAAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEA
AB4CAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAh
AK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAh
AD6R12+nBgAA0SkAAB8AAAAAAAAAAAAAAAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5n
MS54bWxQSwECLQAUAAYACAAAACEA4VE3H88GAADmGwAAGgAAAAAAAAAAAAAAAAAECQAAY2xpcGJv
YXJkL3RoZW1lL3RoZW1lMS54bWxQSwECLQAUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAA
AAAAAAALEAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAA
AAAFAAUAZwEAAA4RAAAAAA==
">
  <v:shape id="Graphic_x0020_11" o:spid="_x0000_s1027" style='position:absolute;
   width:33470;height:3937;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="3347085,393700" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m3287268,393192r-3226308,l53340,391668r-6096,-1524l41148,387096,30480,382524r,-1524l19812,373380r-7620,-9144l3048,345948,1524,339852r,-6096l,326136,,65532,1524,59436r,-6096l19812,18288,47244,3048,53340,,3293364,r6096,3048l54864,3048,48768,6096,15240,30480,4572,53340r,286512l6096,344424r9144,18288l16328,362712r6532,9144l32004,379476r10668,4572l48768,387096r12192,3048l3300984,390144r-7620,1524l3287268,393192xem3336798,362712r-3810,l3339084,350520r1524,-4572l3342132,339852r1524,-7620l3343656,59436,3325368,21336,3299460,6096r-6096,-3048l3299460,3048r7620,1524l3317748,10668r9144,7620l3328416,18288r7620,10668l3342132,39624r3048,12192l3346704,59436r,274320l3342132,352044r-5334,10668xem16328,362712r-1088,l15240,361188r1088,1524xem3300984,390144r-13716,l3305556,385572r10668,-6096l3325368,371856r7620,-10668l3332988,362712r3810,l3336036,364236r-7620,9144l3326892,373380r-9144,7620l3317748,382524r-10668,4572l3300984,390144xe"
   fillcolor="black" stroked="f">
   <v:path arrowok="t"/>
  </v:shape><v:shape id="Textbox_x0020_12" o:spid="_x0000_s1028" type="#_x0000_t202"
   style='position:absolute;width:33470;height:3937;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal style='margin-top:9.55pt;margin-right:0in;margin-bottom:
      0in;margin-left:8.95pt;margin-bottom:.0001pt'><span style='font-size:
      10.0pt;mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-hansi-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman"'>-<span
      style='letter-spacing:-.3pt'> </span>Please<span style='letter-spacing:
      -.25pt'> </span>contact<span style='letter-spacing:-.3pt'> </span>the<span
      style='letter-spacing:-.25pt'> </span>relevant<span style='letter-spacing:
      -.3pt'> </span>competent<span style='letter-spacing:-.3pt'> </span><span
      style='letter-spacing:-.1pt'>authority.</span><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom" anchorx="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><p>- Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Daily doses of voxelotor up to 1500 mg (or equivalent) have been evaluated in clinical trials. There was one overdose in GBT440-031 where a subject took a total of 3000 mg at one time. There were no AEs associated with this event. If an overdose is suspected, treatment should consist of general supportive measures.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: ATC code: not yet assigned</p><p>Mechanism of action</p><p>Voxelotor is a haemoglobin S (HbS) polymerization inhibitor that binds to HbS with a 1:1 stoichiometry and exhibits preferential partitioning to red blood cells (RBCs). By increasing the affinity of Hb for oxygen, voxelotor demonstrates dose-dependent inhibition of HbS polymerization. Nonclinical studies suggest that voxelotor may inhibit RBC sickling, improve RBC deformability, and reduce whole blood viscosity.</p><p><u>Pharmacodynamic effects</u></p><p>The pharmacodynamic effect of voxelotor treatment demonstrated a dose-dependent increase in Hb oxygen affinity as determined by the change in p50 (partial pressure of oxygen at which</p><p>Hb oxygen saturation of 50% is achieved) that was linearly correlated with voxelotor exposure.</p><p>The pharmacodynamic effect of voxelotor treatment also demonstrated a dose-dependent reduction in clinical measures of haemolysis (indirect bilirubin and % reticulocytes).</p><p><u>Cardiac electrophysiology</u></p><p>At plasma concentrations approximately 2-fold above therapeutic concentrations, voxelotor does not prolong QT interval to any clinically relevant extent.</p><p>&nbsp;</p><p>Clinical efficacy and safety</p><p>The efficacy and safety of OXBRYTA in sickle cell disease (SCD) was evaluated in HOPE, a randomized, double-blind, placebo-controlled, multicentre trial (NCT03036813)/ (EudraCT2016-003370-40). In this study, 274 patients were randomized to daily oral</p><p>administration of OXBRYTA 1500 mg (N=90), OXBRYTA 900 mg (N=92), or placebo (N=92). Patients were included if they had from 1 to 10 vaso-occlusive crisis (VOC) events within 12 months prior to enrolment and baseline haemoglobin (Hb) &ge; 5.5 to &le; 10.5 g/dL. Eligible patients on stable doses of hydroxyurea for at least 90 days were allowed to continue hydroxyurea</p><p>&nbsp;</p><p>therapy throughout the study. Randomization was stratified by patients already receiving hydroxyurea (yes, no), geographic region (North America, Europe, Other), and age (12 to &lt; 18 years, 18 to 65 years). The trial excluded patients who received red blood cell (RBC) transfusions within 60 days and erythropoietin within 28 days of enrolment, had renal insufficiency, uncontrolled liver disease, were pregnant, or lactating.</p><p>The majority of patients had HbSS or HbS/beta0-thalassemia genotype (90%) and were receiving background hydroxyurea therapy (65%). The median age was 24 years (range: 12 to 64 years); 46 (17%) patients were 12 to &lt; 18 years of age. Median baseline Hb was 8.5 g/dL (5.9 to</p><p>10.8 g/dL). One hundred and fifteen (42%) had 1 VOC event and 159 (58%) had 2 to 10 events within 12 months prior to enrolment.</p><p>Efficacy was based on Hb response rate defined as a Hb increase of &gt; 1 g/dL from baseline to Week 24 in patients treated with OXBRYTA 1500 mg versus placebo. The response rate for OXBRYTA 1500 mg was 51.1% (46/90) compared to 6.5% (6/92) in the placebo group</p><p>(p &lt; 0.001). No outlier subgroups were observed (Figure 1). The distribution of Hb change from baseline for individual patients completing 24 weeks of treatment with OXBRYTA 1500 mg or placebo is depicted in Figure 2.</p><p>&nbsp;</p><p>Figure 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haemoglobin response at Week 24 by subgroup (voxelotor 1500 mg vs placebo)&ndash;ITT&nbsp;<strong>Population</strong></p><p><strong>&nbsp;<img src="data:image/png;base64,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" alt="" width="727" height="438" vspace="0" hspace="0" border="0" style="width:727px;height:438px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Figure 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subject-level change from baseline in haemoglobin at Week 24 in patients who completed 24 weeks of treatment*</p><p><img src="data:image/png;base64,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" alt="" width="681" height="455" vspace="0" hspace="0" border="0" style="width:681px;height:455px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>The adjusted mean increase in Hb was 1.14 g/dL in the 1500 mg group and ‑0.08 g/dL in the placebo group. The increase in Hb was observed beginning at Week 2 and maintained through Week 24 (Figure 3). Decreases in clinical measures of haemolysis demonstrated the same time course as the haemoglobin improvement.</p><p>Additional efficacy evaluation included change in Hb and percent change in indirect bilirubin and percent reticulocyte count from baseline to Week 24 (Table 2).</p><p>Table 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjusted mean (SE) change from baseline to Week 24 in haemoglobin and clinical measures of haemolysis</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>OXBRYTA </strong><strong>1500 mg QD (N=90)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=92)</strong></p></td><td style="vertical-align:top"><p><strong>P-value</strong></p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin</p></td><td style="vertical-align:top"><p>1.14 g/dL</p><p>(0.13)</p></td><td style="vertical-align:top"><p>-0.08 g/dL</p><p>(0.13)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>Indirect Bilirubin</p></td><td style="vertical-align:top"><p>-29.08 %</p></td><td style="vertical-align:top"><p>-3.16 %</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(3.48)</p></td><td style="vertical-align:top"><p>(3.52)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Percent Reticulocyte Count</p></td><td style="vertical-align:top"><p>-19.93 %</p></td><td style="vertical-align:top"><p>4.54 %</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(4.60)</p></td><td style="vertical-align:top"><p>(4.60)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjusted mean change from baseline in haemoglobin over time up to Week 24 in adults and </strong>a<strong>dolescents with SCD</strong></p><p><strong>&nbsp;<img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAu4AAAHPCAYAAAAMBV/EAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAHYcAAB2HAY/l8WUAAFF8SURBVHhe7d0JvBtV3f9x2rLasrTsO6VUqlIsUGUVhEdaShFQii0FXFgKRYUKiFARkL2A7EsRhCJLFUEUqSibYGV5WPsvCIhcNqGI1LLJIgXO//mO8xun00kySU6Smczn/Xr9XjdzMjfJnUySb849c2YRBwAAACD3CO4AAABAARDcAQAAgAIguAMAAAAFQHAHAAAACoDgDgAAABQAwR0AAAAoAII7AAAAUAAEdwAAAKAACO4AAABAARDcAQAAgAIguAMAAAAFQHAHAAAACoDgDgAAABQAwR0AAAAoAII7AAAAUAAEdwAAAKAACO4AAABAARDcAQAAgAIguAMAAAAFQHAvkJEjR7pFFlkkqEGDBoWt6Ww9lX4PAAAAxUZwL4jp06e7KVOmhEsuCO7x5TgF9azrAgAAoBgI7gU1ceLEoJJ6enqCXnb9NArt9LoDAAAUG8G9oNSLPnPmzHDpv9Sm4B6n3vpaQ2vSxIfbqD772c+G1wAAAKDdCO4FVKm3XVoZ3FWEdwAAgM4guBeMhrxUCu3SqqEy//u//0twBwAA6CCCe4FkPcg0uZ4Ct3rdm0FwBwAA6CyCe0Gol13BOVlivewWzm3ZqloPfVYEdwAAgM4iuCMTgjsAAEBnEdyRCcEdAACgswjuyITgDgAA0FkEd2RCcAcAAOgsgjsyIbgDAAB0FsEdmRDcAQAAOovgjkwI7gAAAJ1FcEcmBHcAAIDOIrgjE4I7AABAZxHckQnBHQAAoLMI7siE4A4AANBZBHdkQnAHAADoLII7MiG4AwAAdBbBHZkQ3AEAADqL4I5MCO4AAACdRXBHJgR3AACAziK4IxOCOwAAQGcR3JEJwR0AAKCzCO7IhOAOAADQWQR3ZEJwBwAA6CyCOzIhuAMAAHQWwR2ZENwBAAA6i+COTAjuAAAAnUVwz6inp8fNnDlzoZo1a1a4RncjuAMAAHQWwb2KqVOnurFjx7r+/fsHobVaab3p06eHv9l9CO4AAACdRXCvYtCgQW7ixIlBIFfv+ty5c8Nr/kPLalfA13oK+N2K4A4AANBZBHdkQnAHAADoLIJ7kxRmy4DgDgAA0FkE9yYR3AEAANAOBPcadNDpyJEjKxbBHQAAAO1AcK8hLawnqwwI7gAAAJ1FcEcmBHcAAIDOIrhXMWXKlExVBgR3AACAziK4V5HlxEsMlQEAAEA7ENwzUkDXiZbitExwBwAAQDsQ3DNSaFVQ7+npCZb1U8tqLwOCOwAAQGcR3DOaPn166tCZZC98tyK4AwAAdBbBvQ5z5851M2fOjErLZUFwBwAA6CyCewXDhw93EydOdDNmzChVQK+E4A4AANBZBPcK7MBTGxKjID958uSgp72MCO4AAACdRXDPQL3uCu0K7xbkbZaZWbNmhWt1N4I7AABAZxHc66RhMzpQVcNoBg0aFIRZHbQ6duzYcI3uRHAHAADoLIJ7k2xaSII7AAAAWongntGUKVPCSwtSD7yCu3rhuxnBHQAAoLMI7hkptNrQGI1117h3iR/AqnHw3YrgDgAA0FkE94wUWtWzrlll9FPj2q1dve46SFWXuxXB3a8BAwYE2zNZSyyxRLgGAADAggjuGSmoaziMgrt627WswK6wpXHudrlbEdxbZ7HFFnP//ve/wyUAAIB0BPeMFNrjs8jYZfup6uYDVAnurUNwBwAAWRDcm6CedtEwGfXEq9e9WxHcW4fgDgAAsiC4V2FnS9XQmEonWlJ7/ARN3aoowV2PM63yjOAOAACyILhXoYNQ42dLrVZaT+t3K4Vf/Z15Du76AqXHpxoyZIgbOnRotPzwww+Ha+UPwR0AAGRBcM9IQ2FUms/dytrKoAjBPe6www5zp59+eriUbwR3AACQBcEdmRDcW4fgDgAAsiC4IxOCe+sQ3AEAQBYEd2RCcG8dgjsAAMiC4I5MCO6tQ3AHAABZENyRCcG9dQjuAAAgC4J7wYwcOTII0HbypzQTJ04M1olXswjurUNwBwAAWRDcC0JBXcF5+vTpwc9awV3lE8G9dQjuAAAgC4J7HRSabQ530+553C3AtyO4X3zxxVEdddRRBPcWIbgDAIAsCO4ZTZ482fXv3z8aqmLil9sha3DXOlaNhvj4bVgR3P0juAMAgCwI7hkptM6dOze6bOKX2yFLcE/S+vpvQb0mTJgQ1a677hrcDsHdP4I7AADIguCe0aBBg4Keaw2NUYDVz7Fjxwbt7dRIcNfjjg/vaQRj3FuH4A4AALIguGc0a9asaJiMlUK72tup3uBu6zc7Fp/g3joEdwAAkAXBvSCspz9ZYuHchsMk12lkmEwSwb11CO4AACALgnsdFJAVoJNVBgT31iG4AwCALAjuGSVnaolXGRDcW4fgDgAAsiC4Z6TQOmPGjIV629s9xr1TCO6tQ3AHAABZENwz0jzuU6dODZfKh+DeOgR3AACQBcE9o+SMMvEqA4J76xDcAQBAFgT3jJJDZOJVBkUJ7pdffrlbfvnlg8fap08fN3jwYPfYY4+F1+bHjTfe6NZYY43oy98KK6zgNttsMzdv3rxwDQAAgAUR3JFJEYJ7pQOIe/Xq5WbPnh2u1XmHHnpo6uNUrbTSSu7FF18M1wQAAPgvgnsV/fv3D0rSQpZVGRQhuA8YMGCh56ZoNXDgQPelL30p/IvyYd99902tJ554IlwDAAC0A8G9Cp24yE5elDZExqoMihDckyG4qLXiiiuGf1E+XHLJJUHtueeebptttomWAQBAexHckUkRgvuSSy65UAguYunvuPXWW8O/Kj8uvPBCd+CBB4ZLAACg3QjuVaSFqrQqgyIE91GjRi303Kh23333YGhHXmgoTNrjTNaECRPcq6++Gv5W5xHcAQDoLIJ7FWnDYtKqDIoQ3F977bVoRhmVplkcM2aMW3fddYPr8mSLLbZw66+/vttwww2Dg2eHDh3q1l577eCyPX6VjrFQYM4DgjsAAJ1FcEcmRQju8sMf/jAKvUsttVTQ0/7WW2+F1+bLaaed5j7/+c8Hj3XrrbcOlnt6ety4ceOiv8FK6919993hb3YGwR0AgM4iuGc0a9YsN2jQoChIGZ2YqQyKEtx32mmn6Dn6yle+ErbmW9oJmH75y1+6T3ziE9HfYjVp0iT39ttvh2u1F8EdAMrh5ZdfdrvttltqPf744+Fa6ASCe0YK7VOmTAmGxihAmfjlblaU4B6fEvKII44IW/Ot2plTjznmmOjvsVpttdWCE021G8EdAMrjF7/4RVCaUWzXXXeNltFZBPeMFJg0jMEui3rh7XK3K0Jwt+dD1a9fP3f66aeH1+RbteAuOvPrLrvsEv1tVjvuuKN75JFHwrVaj+AOAOVzyimnuCOPPDJcQqcR3DOaPHlyEJY0NCb+U+1lUITgrmCpx6j6+Mc/3jXB3Vx11VXBAaz2N1odddRR7qOPPgrXah2Ce/nstddernfv3qn1xhtvhGsB6GYE93whuNdBw2Q0XMbKTs5UBkUI7vp3noVZHczZbcFd3n//fffd7343+jut1ltvPffzn/88XKs1CO7l9OGHHwal40d+9atfRcsAyoHgni8Ed2RShOA+cODAKMgqxHdjcDf333+/23777aO/10rTXz755JPhWn4VIbg/99xzqYXmffGLX3S//vWvwyUAZUFwzxeCe0bqXbdhMTZsRnNsl6XXPe/B/dlnn43Ca9++fd1hhx3W1cHd/PjHP3YrrbRS9LdbnXDCCeEa/uQ9uOtLy1prrRXUcsstF11WoXkEd+TVSy+9FPwnMq3QPIJ7vhDcM1IYmjt3bjSrjIbKTJ06NQjvZZD34H711VdHoXXEiBGlCe7y+uuvu29+85vR32+lkzv95je/CddqXpGGymgqzT//+c/hEnwguCOv5s+fH5wHQ6XPKE1ZaMtoHsE9XwjuGelg1OHDhwdBXVNDimYxIbjnw0EHHRQF1uOOO65Uwd3ceeedbquttoq2g9Xee+/tXnjhhXCtxhHcy43gjiLYb7/9gv9Ewh+Ce74Q3DNSb7sdlGrTQqrHXeG9DPIe3IcNGxYF1VtvvbWUwd2cc845wXSYtj1USy65pPvRj34UrtEYgnu5EdxRBAR3/wju+UJwRyZ5Du7z5s1bIKTqzKJlDu4yZ84c941vfGOB7aLadNNN3W233RauVR+Ce7kR3FEEBHf/CO75QnDPSAehalhMMgipyiDPwf2mm26KngsFUyl7cDc333yz23jjjaPtY3XAAQe4V199NVwrG4J7uRHcUQQEd/8I7vlCcM9IoV2zyWiojIKPfo4dOzaoMshzcNcJiCyQfuc73wnaCO4L0htvnz59ou2kGjBgQBDGsyK4lxvBHUVAcPeP4J4vBPeMFNw1zl0UejTOXcu6XAZ5Du7bbLNNFEavu+66oI3gvjDts+PGjYu2ldW2227r7rnnnnCtygju5UZwRxEQ3P0juOcLwT0jDZWZOHFicNnmcVdptpkyyGtw1xkcF1100ej50NhuIbhXdv311wfB1raZlf5boeMDKiG4lxvBHUVAcPeP4J4vBPcGaT53lfXCd7u8BnebV181ZMiQsJXgnsUxxxwTbTur1Vdf3U2bNi1cY0EE93IjuKMICO7+EdzzheCOTPIa3E899dQodO6zzz5hK8E9q0cffdTtvPPO0Ta0Gj16tHvkkUfCtf6D4F5uBHcUAcHdP4J7vhDca4jP367hMpq3XSdgUrjRCZmYx72z4qHzJz/5SdhKcK/XVVdd5dZee+1oW1ppWJghuJcbwd2fN998M7XQPIK7fwT3fCG416Ax7DowVT8VZHRZM8nYrDKMce+s5ZdfPgqZTzzxRNhKcG+EHsPhhx8ebU+rpZde2vXt2ze43Lt3bzdw4EB3++23h7+VTwR3/wjufowfPz54Tal0ojS7rHryySfDtdAogrt/BPd8IbjXoLBi49jTZpFJLnerPAb32bNnB49JteqqqwZnstVP1YorruhWWWWVaDnPgSMvwd3oud5+++2jbZtWCvI33HBD+Bv5Q3D3j+Dunw4Ib/aMxlgQwd0/gnu+ENxrUEixoTKqtOUyyGNwv+iii4LHpNptt92CNs0qk1Z5lrfgbvThZ9s3rYYOHRqumT8Ed/8I7v4R3P0juPtHcM8XgnsNaYElWWWQx+C+9957R8/BmWeeGbYWT16Du2hojG3jtFJ4/973vufuuuuu8DfygeDuH8HdP4K7fwR3/wju+UJwRyZ5DO7rrrtuFCDvu+++sLV48hzc11lnnWgb16qVVlrJff3rX3fXXnut+9e//hXeQmcQ3P0juPtHcPeP4O4fwT1fCO7IJG/B/fnnn48C48c+9rGwtTgUbF944YWgdAIpndVUl1955ZVwjXx46KGHXK9evYIDUrWtdTDwVlttFbQtvvji0XOQVqNGjXLnnXde8Le1G8HdP4K7fwR3/wju/hHc84XgjkzyFtyvueaaKCB+4QtfCFuL49Of/rRbc801gxowYEB0eb311gvXyI+nnnoqmEFJPerLLrtscFlt8+fPD4Kcpohca621oucjrTbeeGN39NFHu3vuuSe81dYiuPtHcPeP4O4fwd0/gnu+ENyRSd6C+7e+9a0oFB577LFhK1qp1jzuGq6k5+Izn/lM9Nyklc7Ouv/++wez0rRqiBDB3T+Cu38Ed/8I7v4R3POF4N6Edfd5Lrz0H8nlbpK34K4eXAuCv//978NWtFI9J2B69tln3QUXXOB22mmnqge4any/TqKlqTw1VMgXgrt/BHf/CO7+Edz9I7jnC8E9I83hrnARnwpSQV0/DcG9PV5//fUFwt9bb70VXoNWavTMqe+884677rrr3D777BPMqR9/7pK16aabuh/+8IfugQceCH+7MQR3/wju/hHc/SO4+0dwzxeCe0bDhw+PzqBqpaAeP3Mqwb09ZsyYEQU9DctAezQa3JNmzpzpjjrqKDds2LDoeUwrHRB70EEHuZtuusl99NFH4W9nQ3D3j+DuH8HdP4K7fwT3fCG4Z6TQbmdQNcmgTnBvj+9///tRuJs0aVLYilbzFdzjdJDr2Wef7UaMGBE9p2mlmYPGjBnjfvKTn7iXX345/O3KCO7+Edz9I7j7R3D3z1dwHzRoUPB+nmWmMa2jdfU7ldhJMOMjH8qA4J6Rhsmo192GyagU1NVuCO7tse222waPRaU5w9EerQjucW+88YabPn16cGKtFVZYIXqO0+pzn/ucO/nkk92sWbPC314Qwd0/grt/BHf/CO7+NRvcLYRb1Qru+hywdSsFd/3n1tYhuCOVQrvtJFYK6uqJNwT39ojPH/7iiy+GrWi1Vgf3pDvuuMMdfvjh7pOf/GT0fKfVxz/+8eA/L4ceeugCY+g1daUOYp49e3Z4i6iX/sMR36b9+vVjm3pEcPcjuZ/27duX/bRJyW265JJLNrRNkyFcP6sF94kTJy6wbqXgbrepIrgjlQJ6cmdLBnWCe+v96U9/il6sCmxon3YH9zj1np9++ukL/Lcla+lkUaeeeqr73e9+R9VROj9C2vZUaZvefvvt4bODRhHcm/fVr341dR9V8dpvrHy+9hXcFcYla3DX71gvfVpw17GFuk6B3X6WCcE9I+1IOvGM/j1jpaCun4bg3nqnnXZa8DhU3/jGN8JWtEMng3ucjjX56U9/6saNG+eWWWaZaH+g2leaxlNn0T3iiCOCnjm9D/7jH/8InyFkRXCvn/Yz7W+XXnqp++53v5u6f1Ktq7XXXjs4e3YjsgR3Uym4Ww++9gGCO6rSzpEsBXX9NAT31tt1112j7X/JJZeErWiHvAT3JM3jr14g2y+ozpWOTdhyyy2DqT/V06mTbD3++OPugw8+CJ8txBHc03344YfBfqP9R6FM+5P2q1rHvlCtL4V2DZtpRLPB3dqsB5/gjrolgzrBvfVWXHHF4HGoOPiwvfIa3GWzzTaL9otkqWdY+018Kleqdi233HKp27PRWn/99YOTbem4BX3p/uMf/+j+/ve/h89gOZU9uL/yyivBfmC959o/tJ/4+iLOa7+xqvba33777d3o0aPDZ7A+zQZ3C+pppcddFgT3OunfMyrNZkFwb69HH300epGuvPLKYSvaJc/BXW/yK620kttkk02C/UM9QppZRmduXWuttTJ9UGBByW2q43zWXXddN2rUKLfKKqu4c845xx133HFu/PjxwTo6cNVen/WUwtXmm2/uvv71rwezV1x//fXusccec/Pnzw8fSfcqQ3DXf1vUyaLec/0XRkMct9hii4Z7z7WfaX/TfqeTtWk/HDBggNtoo42C6xXU9Zq31/4zzzwTPhJklXztazvqM7fZbZoW3Cv1mmsdtceDexI97qhKJ/3RB5d2EisF9fh0dAT31rr44oujbf/lL385bEW75Dm4y5tvvhnM8a+zr/bu3dttuOGGwbLa0Zj4NtW4dh0QXm2bvvDCC+7WW291559/vjv44IODXrB11lknet3WW4MHDw7CgmYM0uv/zjvvdHPmzAnvrfi6KbjrvyfqPdd/U/RfFes9T3tes5T2G+0/3/72t4P9SfuV9q808f1Us47p5G289psT36bqCFlttdWa3qYEdz8I7hlp59HOYT3uKgX1+E5FcG+tr33ta8FjUJ1xxhlhK9ol78E9jnnc/WtmHvd33nnHPfLII+7nP/+5O/74492ee+4ZnPW40YOL1Ymi4VGaUeSkk05y1113XTBN3b///e/wHouhaMHdes9/+ctfBv8dsd5z/dck7XmqVUsvvXQw1bL1nv/sZz8L9pO33347vMf6MY+7f5w5NV8I7hnpTSbtzKlqNwT31lpvvfWiN/x77rknbEW7ENzLrVUnYPrb3/4WTC+n/euQQw4JhuJoSI691ustdabsuOOOQSi+6KKLgvMBvPTSS+G95Uteg7t6z++6664gAKv3XM+9/tuStr2zlPWe678wF1xwQdXe82YR3P0juOcLwT0jHcWsD4TJkycHPe/6qaAePyCC4N46epO3D4FGj2hHcwju5dbuM6e+++677v/9v/8XnB35hBNOCM6oq/cfnVjL3gvqKf2efl+3o9vT7er2dT+d0sngrmMIdCyB9Z7rGAMda9Bs77n+m6L/qljvuf7b0k4Ed/8I7vlCcM9Ive0K7ArqVgrq8V54gnvr6EPAPiD+53/+J2xFOxHcy63dwb0a9aCrJ33q1KlB+FUPe/w/cvWWevh32GGHoMdf+/ltt90W/Ceg1doR3F9++eWo9/ywww4Ljhlopvdc48e1raz3vF3bKiuCu38E93whuGekMe1pQ2XiCO6tow8J++D4wQ9+ELainQju5Zan4F6JxrhrrLvGvGvsu8bAayx8cmKBrBXvRfY1BjvOV3B///33g95zzchz8sknB8cDqfdcs62k/V21SscexHvPdWxCJ3rPG0Fw94/gni8E94z0xp+H4K6efr2xxo/KThN/E44P52lUp4O7TUuluvnmm8NWtBPBvdyKENyr0Ww0mpVGs9NYz7NmrbH3lXorbdaT559/Pry3bOoN7uo99/k3WO95u//T0EoEd/8I7vlCcM9Iw2QU3jXWXZdVCur6aVoZ3G1qJDvdb7Xgrg+T+OOyGXGa0cng/sYbb0QfNCqm+OoMgnu5FT24V2JjvdVb7WOst+YZ33jjjd0ee+wRzHN/zTXXuIceesj961//Cu5P/w1YffXVo/X79u0bvK/aAbTqPdc5K7Se9Z43818D9Z5rBp+99tor6j3XNMadHNvfSgR3/wju+UJwz0hhOFkK6vpp2tHjbgG+UnBPu16hPf44G9HJ4K4edvsQ0r9v0RkE93Lr1uBejc2uYnOTaxs0Mzd5tZNU9enTJzi5Tdp1WSo5Tl8z9RS997wRBHf/CO75QnBvQjKo5yG4ayy+ro9TL318vvmsNDzFasiQIcHtdiK4a0y7fThprDs6g+BebmUM7pVoPvPHH388OhvoPvvs47bccsuGzwaatTQzjvWe28w43dx73giCu38E93whuNeQ7KmuNjSm24J7/APDqhPBfbvttovuXweHoTMI7uVGcM/mH//4R/A+fOmll7ojjjjC7bLLLkHHh87mG38vrVbqPdd89pMmTYp6z1988cXwHlANwd0/gnu+ENxr0JtoXHw5j8E97fpGh8o8+OCDUV1xxRXB7XYiuGvedt23qoz/+u0kfVHSqe6tFl100eiyzmWQVwR3/wjuzfnoo48WGNueLE3RqKGA9J43h+DuH8E9XwjuNegNVb0nVvFlBXX9m9LkIbhL8mBUra9e92Z0aoy7zpCq+1Vp9gS0nw6WS6s8I7j7R3Bv3r333uuWWGKJ4OBXvaetssoqbo011nBjx44NDiLV9WgOwd0/gnu+ENxrsNCYVgrq+mlaGdztS0OyxMK8hXNbttJMOM3qVHA/44wzor9DsysAWRDc/SO4+/Hcc8+5Qw89NDh2SCFewV3LakfzCO7+EdzzheBeg3rUrYc9WQrq+mna0ePeKZ0K7l/60pei4K65i4EsCO7+Edz9a8eZU8uG4O4fwT1fCO7IpFPBfeWVV46Cu+ZaBrIguPtHcPeP4O4fwd0/gnu+ENyRSSeCu4KXhfaVVlopbAVqI7j7R3D3j+DuH8HdP4J7vhDckUkngrtOemLBfddddw1bgdoI7v4R3P0juPtHcPeP4J4vBHdk0ongrlOPW3A/7bTTwlagNoK7fwR3/wju/hHc/SO45wvBvQ6atUXTLManWowfnNrNOhHcNa+xBfe77747bAVqI7j7R3D3j+DuH8HdP4J7vhDcM9LJZvr37x+cyEhB0sQvd7N2B3edJdBCu6ZMA+pBcPeP4O4fwd0/grt/BPd8IbhnpAA5d+7c6LKJX+5m7Q7u1157bXB/qm233TZsBbIhuPtHcPeP4O4fwd0/gnu+ENwz0tlIdSIjDY1RmNRPne1O7WXQ7uB+yCGHRMH9+9//ftgKZENw94/g7h/B3T+Cu38E93whuGekEzHZMBkrhXa1l0G7g/tnPvOZaDv/9re/DVuBbAju/hHc/SO4+0dw94/gni8Ed2TSzuD+1ltvRaFd9frrr4fXANkQ3P0juPtHcPfn4YcfDkpn2z766KOjZTSP4J4vBPeM1Nve09MTDJGxse6iHncNmdEwmnh7t2lncP/9738fhfaNN944bAWqu+iii9w+++wT1Oqrr+723nvvaBnNI7j7R3D3Y9q0aW7YsGGp9cQTT4RroVEE93whuGdkQdLKpoTUcJnhw4cHPxXuu1U7g/sxxxwTbedvfetbYStQ3ezZs92ll16aWmgewd0/gjuKgOCeLwT3jBQibTy7fmpZ7Kd62+1yN2pncP/CF74Q3JdKc+cD6DyCu38EdxQBwT1fCO4Z2awy6mm3Od1nzJgRhUtdVlu3amdw/9jHPhYF9+effz5sBdBul1xyidtuu+2CWm+99dzWW28dLaN5BHcUAcE9XwjuGamXXcFdw2FsTLuFeQV2hUwF+m7VruB+3333RaFd2xdAZ91+++2pheYR3FEEBPd8Ibgjk3YFd32IWXDXwYUA0K0I7siz1157Lahjjz3WTZo0KVpGZxHcM9IYdg2J0VCZZJVBu4L7brvtFgX3qVOnhq0A0H0I7sirK6+80i277LKpde6554ZroRMI7hlp5hgLlPHq5nHtce0K7quuumq0bTVLCAB0K4I7gHoR3DNSQO/medpraUdw13y7FtpXWGGFsBUAuhPBHUC9CO4ZaZiMDkrVCZiSVQbtCO6ab9uC+8477xy2AkB3IrgDqBfBPSMLlGlVBu0I7jrDpW3Tshw7AKC8CO4A6kVwRybtCO5DhgyJgntZ/pMBoLwI7gDqRXBHJq0O7nPmzIlC+2KLLeY+/PDD8BoA6E4EdwD1IrhnpDHudqKlZJVBq4P7L37xi2h7brPNNmErAHQvgjuAehHcM1Jo15lRNfZa4VI/dbCqqgxaHdz1AWbBvZvPQAug3PT+NnTo0KDWXXfdYIigLb/33nvhWgCQjuCeUXw6SIXLnp6eYFmXy6DVwX3TTTeNgvtNN90UtgJA99E5KtIKAGohuGekoTITJ04MLqvHxELmyJEjg7Zu18rg/vbbb0fbUzVv3rzwGgAAABiCe4NsDveynJSplcH9lltuiUL7sGHDwlYAAADEEdyRSSuD+3HHHRcF929+85thKwAAAOII7hlpqMygQYOigBmvMmhlcB8xYkS0La+++uqwFQAAAHEE94wUKm1WmXhNnTo1XKO7tTK49+3bNwruzz77bNgKAACAOIJ7RjoIddasWeFS+bQquNvtqgYOHBi2AgAAIIngXoXCutXw4cODcBlvsyqDVgX3s846Kwrue+21V9gKAACAJIJ7FclhMZWqDFoV3HffffcouF944YVhKwAAAJII7sikVcF9tdVWi4J7mYciAQAA1EJwr2HGjBkVT8Gvdl1fBq0I7k8++WQU2gcMGBC2AgAAIA3BvQZNAdnT0xMuLUjtur4MWhHcL7vssii4f/GLXwxbAQAAkIbgXoNCZbXgruvLoBXBfb/99ouC+ymnnBK2AgAAIA3BvYaJEycGveqar33mzJlRaVntY8eODdfsbq0I7p/4xCei4H7XXXeFrQAAAEhDcK9h7ty5wVh2C5jx0lSQur4MfAf3l19+OdqOffr0cfPnzw+vAQAAQBqCe0YK6PEe90rDZ7qV7+B+/fXXR8F96623DlsBAABQCcEdmfgO7ocddlgU3I888siwFQAAAJUQ3JGJ7+C+2WabRcH9xhtvDFsBAABQCcEdmfgM7u+8804U2lX//Oc/w2sAAABQCcEdmfgM7rfddlsU2j/96U+HrQAAAKiG4F6DTsOvqR81LaRmkUmWpoOcMmVK15+u32dwP/7446Pgru0KAACA2gjuVfTv3z8Il5qvXSFd00IqpFtpWe3x9bqVz+CubWbB/corrwxbAQAAUA3BvYrp06dnnvZR66lnvlv5DO5LL710FNyfeeaZsBUAAADVENyRia/g/sADD0ShfZ111glbAQAAUAvBvQYbBlOpdH0Z+Aru55xzTrTtxo8fH7YCAACgFoJ7DfEx7ZWqDHwF96985StRcD///PPDVgAAANRCcEcmvoL7GmusEQX3Rx55JGwFAABALQT3GtSjXmnKQrXT457dU089FYX2sgwxAgAA8IXgXoMC5ty5c8OlBamdMe7ZTZs2LQruo0ePDlsBAACQBcG9BgXzmTNnhksLUjvBPbv9998/Cu4nnXRS2AoAAIAsCO41aCiMgqadIdVKy2rXSZjKwEdw/9SnPhUF9zvvvDNsBQAAQBYE9wxmzJjhhg8fHoVOlc6S2u7x7RpTH38MlU4OlVxP1axmg/srr7wSPZbevXu7999/P7wGAAAAWRDcC0JncdWXBaMvDfHlOAX3SgfUNqrZ4H7DDTdEwX2rrbYKWwEAAJAVwb0gRo4cuUAPv3rbFYLTet19BfcHH3wwqiuuuKKp4H744YdHwf173/te2AoAAICsCO4Fod519brHKQSnHTibHCrTaIiP34ZVo8F9iy22iG7j17/+ddgKAACArAjuBVFPcE/SesnfzWKTTTaJasiQIQ0H9/feey8K7apXX301vAYAAABZEdwLop6hMknqcW/2QNpmxrjfcccdUWgfOnRo2AoAAIB6ENyrSOulnjp1ajB3u0KofjbSk92I5MGoCuMK87VYwM/SM19NM8H9hBNOiIL7gQceGLYCAACgHgT3KhSMk0NUFD6tl9tCcbvo8VgAjt+vPQ57nPF14u3NaCa4jxo1KnosP/3pT8NWAAAA1IPgXoN6qhWYVbqsnm6FeQv1+lkGzQT3ZZddNgruTz/9dNgKAACAehDcM1KvtQV1DZdRiJ81a1Z4bfdrNLg/9NBDUWhfa621wlYAAADUi+BehcK5wroFz8mTJ0cBXj3vWQ4M7RaNBvdzzz032n577LFH2AoAAIB6EdyrUO+6jQ+fO3euGz58eBDmdVkHi+rgVIX5Mmg0uI8bNy4K7uedd17YCgAAgHoR3KtQaFc4V4BXaNdlhXajyxo2UwaNBncNj7HgrmEzAAAAaAzBvQYNh1Evu6rMGgnuOhDVQrsOUAUAAEDjCO51sl52DZXxMc1iUTQS3K+44ooouO+4445hKwAAABpBcK9BoTNOw2YsjKoY417ZAQccEG2nE088MWwFAABAIwjuNSh0xmnZhs3MmDEjGPdeBo0E96FDh0bB/Y477ghbAQAA0AiCew0KnRoWY6Vlo2EzBPd0r776ahTaVe+99154DQAAABpBcK9h7NixwfCYeBnN5V6Wce71Bvdf/epXUWjfcsstw1YAAAA0iuCOTOoN7kcccUQU3L/73e+GrQAAAGgUwT0DTQmp8ew2XEaXZ82aFV5bDvUG96222ioK7jfccEPYCgAAgEYR3GvQUBgLoMnSSZnKEuDrCe7vv/++69WrV7SdXnnllfAaAAAANIrgXoOCp+ZttzOmKqhrnLuWNcY9Pua9m9UT3P/whz9EoX2DDTYIWwEAANAMgnsNmjVGQ2OMpoJUIDXxy92snuB+0kknRcF9woQJYSsAAACaQXCvIW2ojHraRb3vgwYNCi53u3qC++jRo6NtNW3atLAVAAAAzSC4Z6CDU9XTrirbQammnuC+3HLLRcH9qaeeClsBAADQDIJ7FRoiY2Pba9F68SE13SZrcH/44Yej0L7mmmuGrQAAAGgWwb0KjW9XANXsMToRU/wMqlZq1/Var5vPopo1uJ9//vlRcNe2AQAAgB8E9xps/nY7a6qFUpW16fpu7m2XrMF9/Pjx0fY555xzwlYAAAA0i+COTLIG97XXXjsK7g888EDYCgAAgGYR3JFJluCug3gttC+zzDJhKwAAAHwguCOTLMH9yiuvjIL7DjvsELYCAADAB4I7MskS3DW/vQX3448/PmwFAACADwR3ZJIluG+44YZRcL/tttvCVgAAAPhAcM9IJ15Sj7LNJBOvMqgV3DWPvYV21TvvvBNeAwAAAB8I7hlpjnbN154M7WWZq7xWcL/xxhuj0L755puHrQAAAPCF4J7RoEGDMp9FtRvVCu5HHnlkFNwPO+ywsBUAAAC+ENwzmjp1ahDe42dNtSqDWsH9c5/7XBTcr7/++rAVAAAAvhDcM0oOkYlXGVQL7vPnz3d9+vSJgvvf//738BoAAAD4QnBHJtWC+1133RWF9k9+8pNhKwAAAHwiuNdBM8vMnDlzoSqDasH9lFNOiYL7fvvtF7YCAADAJ4J7RpMnT47Cabw020wZVAvuO+20U7Q9LrvssrAVAAAAPhHcM1IonTFjRtDDrsv6qQNWGePu3IABA6Lg/pe//CVsRTd47bXXgi9maXXnnXeGawEAgHYguGekGWV6enqCy+plnz59ehDkFVbLoFJw1/AhC+2rr7562Ipuojn6VToB2ahRo6JlAADQXgT3jBRQNVxGFNotrFpbt6sU3C+88MJoW+y+++5hK7qRnusDDzwwXAIAAO1GcEcmlYL7nnvuGQX3s846K2xFNyK4AwDQWQT3OqinPXnSpbLPKjNw4MAouN9///1hK7oRwR0AgM4qXHC3kNhuGhKjse06GDV+/514LJ2QFtyfffbZ6Pno169f2IpuRXAHgPI48sgjU0snXUTnENwz0n3OnTs3umw68Vg6IS24X3311UGbasSIEWEruhXBHQDK4+STTw5KHZbbbLNNtIzOIrhnpFllNKtGfDrIsWPHBu1lkBbcDzrooOj5OO6448JWdCuCOwCUj06yqJ525APBPSPNKmPDZKwU2tVeBmnBfdiwYdG2uPXWW8NWdCuCOwCUD8E9XwjuyCQZ3OfNmxc9F6q33347aEf3IriXzzXXXOO++MUvphaAciC45wvBHZkkg/tNN90UPRebbrpp0IbuRnAvJzvhll77Rx99NCfgAkqG4J4vBPcaNJuMhshUKo1zL4NkcD/qqKOi5+LQQw8N2pDdKqus4hZffPGg+vTpE11eeumlwzXyJ+/B/dvf/nbwJVKlYVx2mS+WfqiX/de//nW4BOTL1KlTUwvNI7jnC8G9Bt2XxrKnhXarMkgGdx1hbs/FddddF7ShPu+9915Qiy22mHvzzTeDy3mW9+D+4YcfunvvvTeoddZZJxjmYctoHsEdefX444+7CRMmBLXxxhu7HXbYIVpG8wju+UJwr0E96ro/m1VmxowZ0bSQZRIP7gpICpv2XMyZMydcC43Qtvz3v/8dLuVXkYbKfOITn3B//vOfwyX4QHBHEey3337uxz/+cbgEHwju+UJwz0iBXcNmFOB1/8OHDw+W1V4G8eBuU2KqhgwZEq6BRhHc/SO4+0dwRxEQ3P0juOcLwb1O6m2fMmVKcBbVTj+WdooH91NPPTX62/fdd99wDTSK4O4fwd0/gjuKgODuH8E9XwjuGWiudoV19bLb/Wtsu9rKOI/7zjvvHG2Hn/zkJ+EanadQofGNaXX//feHa+UPwd0/grt/BHcUAcHdP4J7vhDca7CwbkFdw0TKKB7cV1hhheh5eOKJJ8I18uHBBx8Maq+99nKHHHJItJxnBHf/CO7+EdxRBAR3/wju+UJwr8Hur1JpyEwZWHDfYIMNor991VVXDa/Nn8MOO8ydfvrp4VK+Edz9I7j7R3BHERDc/SO450vhgnu7aR5Y9bRXqzKw4K5p9iy4jxkzJrw2fwju/hHcy43gjiIguPtHcM8XgjsyseAeHyZz5plnhtfmD8HdP4J7uRHcUQQEd/8I7vlCcEcmFtyXWGKJKLjfd9994bX5Q3D3j+BebgR3FAHB3T+Ce74Q3AtEJ4Cy0Kzq6ekJr1lYfD0fZ3e14G71sY99LLwmnwju/hHcy43gjiIguPtHcM8XgntBTJ8+PTj5k9HY+vhynM2AY7ReM2PxL7vsMrfLLru4wYMHB6F9+eWXd5tuuqn7/e9/H66RPwR3fzST0vbbb+9WXHFFN2DAgOBy3mdXIrj7R3D3Q8Fy5ZVXTq0XXnghXAuNIrj7R3DPF4J7FXbwaa1qh2QYV2+7QnSy1z2tXb/XaK/7aaedFvSuH3300e7xxx8PAqZ+almB85JLLgnXzBeCux+/+93v3HLLLRccpD1nzpygLr744qBN1+UVwd0/grs/L7/8clATJkxwxx13XLSM5hHc/SO45wvBvYr42VErlY9hKFmo11y97nG6/2TPp5bVHpfsrc9KHyrbbrutO/TQQ8OWBe2xxx65nQ6T4O7H5ptv7o4//vhw6b9+8IMfBNflFcHdP4K7f9/5znfcj370o3AJPhDc/SO45wvBPSMFdPU6xmm5m4O7bqdXr15u7ty5YYtzd9xxhzvmmGMoiqIoiipBnXDCCQT3HCG4Z6QQq6BuQ1D0U8vJkNwqnRgqoyER6623XjDGPY3Gveu+rEaMGOHOOecc9/TTT4drdA497vXR8QoHH3xw8AUv/pyutdZa7he/+EW41n/tueeeC62ng6dvuummcI3OosfdP3rc/aPH3T963P2jxz1fCO4Zqdc6behMshe+VRS+473mCkmVwrjWi4d8Pc5kb31W06ZNC6aA3GGHHdzs2bPdG2+84X72s5+5rbfeOuiNHz9+fHCwYnK7bLLJJu7YY491999/f3hL7UVwr+7NN98M9om99tprof16zTXXDGaP+c1vfhME+qWXXtpdcMEFwYFzd955Z3BZbSeffLL79re/7dZdd90Ffr9fv35u7Nix7qc//an75z//Gd5jexHc/SO4+0dw94/g7h/BPV8I7nXQkBENRbGKDyFpBwX1eEAy1stu4dyWrRTym6HhMfGeWAX5oUOHBu1GAU1BTYFNwS1+/wMHDnTf+ta33M033xyu3XoE94U9++yz7vzzz3ejRo1a4PlRDRs2zH3/+99399xzT7j2f6lNX9yWXXbZ4EBlXU6upy9o+qI2fPjwhW77C1/4gjvrrLPcU089Fa7degR3/wju/hHc/SO4+0dwzxeCOzKxedw/+9nPhi3VzZgxwx100EFu7bXXXiDELbPMMkEv/dVXX+1ef/31cG3/CO7/8dBDDwUHl2r6zvjzoNpuu+2C0PDkk0+Ga1eXdR53fXE899xzF/qiqdp4442DA1tbffIugrt/BHf/CO7+Edz9I7jnC8E9o1mzZi3Q62waGTteRPUG97h77703mD5yo402iraflbafQt4zzzwTru1HmYP7Lbfc4g455JDg+IT4tl5qqaXcmDFj3OWXX+7+8Y9/hGtn18gJmF577TV31VVXBTMQ6Utb/PHoS52+3OlLnm8Ed/8I7v4R3P0juPtHcM8XgntGNm48OWtL/HI3aya4x2m4hIZNaPiEBTirz3zmM8Gcxg888EC4duPKFNzfeuut4LiDvffeOzhBUnybrrHGGu6AAw5wN954o/vwww/D32iMjzOnariUhk1p+FT8cWrM/Lhx49yVV17p5s2bF67dOIK7fwR3/wju/hHc/SO45wvBPSOFC5upRZdFvfB2udv5Cu5xOkbgiiuucF/5yldc3759g9u30gGPOvCx0bOzdntwf/7554ODRHfccccFtptqww03dEcddZT705/+FK7th4/gHqd9SlON6UDm5N+gA57PPvvshmcoIrj7R3D3j+DuH8HdP4J7vhDcM5o8eXIQKGzcrv1Uexm0IrjHffTRR8EsJjqQVrOa6L6sdJZOTT94zTXXBLPaZNGNwf3hhx8O5tPdbLPNFtg+Kp0o64wzznBPPPFEuLZ/voN73F//+tcgqFeaoUgBX/tgVgR3/wju/hHc/SO4+0dwzxeCex00TEbDZawanWKxiFod3JM0a4lmOdFsJ8kgp1lNNDuKZkmppFuC+2233eYmTZrkBg8evMA2WHLJJd1uu+0WzLH/yiuvhGu3ViuDe5yGymjIjIbOaAhN/O9eZ5113De/+c2aMxQR3P0juPtHcPeP4O5fK4K7MlT8vT1+7pk06tSLr5+UnAxBea1bEdwz0k6WpKEe7ZrHvdPaHdzjNOuJPtw0C0r8hWmP54c//KF78MEHg3U1i4qmO1x55ZXdCiusEFxWW9689NJLwQmPhgwZEvwd66+/frCsnuef//zn7qtf/apbfvnlF/hbV199dTdhwoQgPH3wwQfhLbVPu4J7UrUZinTQqw5+1UGwyW2qLztaVjsak9ymGsLGNvWH4O5Hcj/VF3z20+Ykt6n+E+5rm6rTU7dpnZ8WuiuxkG9hXMccqoyFers9m0ik1peBoiK416AdxQ5ItctWtvOVQSeDe9yrr74anBRq9913D+YU12Oy0kwqmmNeZ2998cUX3d/+9rfgstp8j/duxqOPPhp8qTj88MODy++++27wU/8lSP5Nmi9fPR3a3zqtU8E9TtNIajpJTSsZ304K9pW2qdp1GfXRNmObthbBvXm19tPHHnssXBNZtXqbWlC3YJ0M8kkWxE1akI/fngX5PHxutgLBvQY9+dWKMe6do1lSNFuKZk3R7Ck6m6tOApWkoLf44ou7VVddNRelNy0N9UmjLx+aGea0007L3VCPPAT3uPgMRdW26aGHHhp8eUt7LqjKVW2b6qy5ei94+eWXwxY0guDeuDlz5gRncua177+qbVO16/pmJIO4BfdKJ4vUdfEedgvuNhIiGdSTt99tCO4ZNbujFl0eg3tSnz59Uk/qpDY99ryUHmels+6qfdFFFw2X8iVvwT1O26zaNk17HqjqVWs/tfX69+8fnOBL05GeeOKJ7tprrw1m3FIvHaojuFenfUj7kvYp7Vvax7SvaZ+rdz+lslerP6N8B3extuS63YjgjkyKENw124rOEpqkHnfNTKIemjzU5z73uaAnKI0+yD//+c+HS/mS5+CubVZpm2re+C222CL1uaAqV7X9dOeddw6OMUgeh5EszdevTg9N7XreeecFJwd77rnnwlsBwf0/NL2t9g315moctfaZ5LkekqV9b/PNN3cbbLABr33P1erPKN/BXfuLlm2ojC0zVKbktGPZsBibGlLf+iuNyeo2RQjumvO9X79+wfAJHdCqf6PqstoanQ++FXQmWYUejR/UdtU0lxq7rWW16/o8ynNwT27T66+/3t11112536Z5ltymv/3tb4NwldymmtXoj3/8o7v00kvdEUcc4XbZZZdgVh/12uk9I610LIdmjBo7dmzwxVqzCOk+0v5j1s3KFNw1la9OrqeDyTW9q2aN0tm0k+fwiJf2Ie1L2qe0b2kf074Wn0kruZ9qH9W+ymu/ccltqgB8ww03NLRNbRiLlcJ1MmhbcK+Up5JB34K7BXNdrtUj300I7hlpJ9C/iLSj2A6hGWUU3stAL1793XkO7qIPhl133TWY+109Mrrs40ysvqnXUT0advIhHWyp5Tz3RuY5uEt8m/bu3dt96lOfyv02zbv4NtW0pfpwrGeb/uUvfwmOQ9E5BjQjknrqNIZW+3ylWm211YL1tL5Crc7voNvpRt0Y3DUzlmaCOvPMM4P3C80Gphmx0p5rK+0T22yzjdt///2DfUX7jDpfsorvpzqeSTNQ8dpvTnybavrhVVZZxds2taCe7DE3dr31wFsQt2Cv96F4ULdgb0GeHncEtCMMHz48COq2w2jsHcE9n3T0ezefObUT8h7c45jH3T+f87hr+k69p6in/eijjw7Onqwe+KWWWip4n0kr633Vl3HrfdUHc7vOY9AKRQ3umt3r7rvvdpdffnkw69WXv/zl4Iuy3svSnjuVwp/O6qwZwXSODk0koP806rwNPjGPu3/tnsc9Gdwl2XOfZOHdqlLvfTcguGek3nbtaCrbwdTjrvBeBgT31iG4+0dw969dJ2DSidU0tE1j4jU2fsSIEcG83PEP5WTZeOevfe1rwYw31113nZs9e3buX1d5Du46V4ReQxoioc+9ffbZx2211VZuxRVXTH0OrNZaa61gpiedKE3T8f7ud79zzzzzTHirrUdw948zp+YLwR2ZENxbh+DuH8Hdv06fOfWdd94JOkp0grITTjghmGFE70caFpcMj/FST5xOxKapVi+44ILgbMQvvPBCeKudlYfgroMR//CHP7iLL744GAqx0047uY9//OOp29JK45z1H+jx48cHJ8BT7+bDDz/s/vWvf4W32jkEd/8I7vlCcM9IQ2UqVRkQ3FuH4O4fwd2/Tgf3ahQ+dTC6Apte+3qsOhtxMnDGSwet69gSnX332GOPdVdffXVwPMybb74Z3mrrtSu460vPI488En3p2WuvvTJ96VlvvfXcjjvu6CZNmuQuuugid/vttwcnt8szgrt/BPd8IbhnpNkPkoFd49vVXgYE99YhuPtHcPcvz8G9Ep2k7fHHH3e/+tWvgpOa7bvvvsFUdyuvvPJCITVeOqGbDqrU/q6ZqXSwpQ669M13cNeBg40MM9KUiV//+teDYUaakUlnySzCe1Iagrt/BPd8Ibg3QWPd40c2dzOCe+sQ3P0juPtXxOBezT//+c9gWrtp06YFU/yOGTPGDR06NDjTZjLcWum1qoMwdTCmgsxll10WHKSpgzUb0Uhw15SZ999/f3Bgr6bSVOeRDuzVFJtpj1nVjQf2VkJw94/gni8E94zswNR4Wa97GRDcW4fg7h/B3b9uC+7VqFPm5ptvdmeffbY76KCDgoMtddBlMhDHSwdtbrnllu4b3/iGO/XUU90vf/lL99hjj7n58+eHt/ofmtrygAMOcIMHDw5+b8011wyWk1NePvXUU+6mm24Kgr2u33bbbYOpMpP3Gy+bVlFTadq0it06lWYlBHf/CO75QnDPKDlMRqWeDmaVySeCu38E93IrU3CvRAdfPvTQQ8HBmDooUwdn6iBNHayZDNHxUkgfPXp08EVAPeOaAlNDePS6108tq6dfoVs9+jqlfNrtqDSt4qc//elgWkX9nk2rqCk2QXBvBYJ7vhDckQnBvXUI7v4R3P0juFengzZ18KYO4tQQGAV1HdwZD93qNdfMLWk0l318XfXwb7/99sG0iueee27bp1UsKoK7fwT3fCG4V6EJ/+0EAGkHp8ZLQ2fiJxDoNgT31slzcH/iiSeCHkWVTp6iIGLLP/vZz8K18ofg7h/BvTHvv/9+MGRGQ2d69eoVnBMkjdp1fV6mVSwqgrt/BPd8IbhXobBus8bUCu4KMt083p3g3jp573HXgXBplWcEd/8I7s3TTDU6oDWN2nU9mkNw94/gni8Ed48s5HcjgnvrFGWoTJEQ3P0juDdPX3iXXnppd9RRRwVndn3jjTfcLbfcEiyrPe9fiIuA4O4fwT1fCO5VaLqsLFUGBPfWIbj7R3D3j+Dux9NPPx2MW9c+2rt372BOeS2rHc0juPtHcM8XgnsVCqq1iukg84ngXm4Ed/8I7v6168ypZUJw94/gni8E9yo01aP1qmscu4bCxHvatawTd5QBwb11CO7+Edz9I7j7R3D3j+DuH8E9XwjuGSm0Juds17Lay4Dg3joEd/8I7v4R3P0juPtHcPeP4J4vBPeMNC2kguugQYOC3nf91HI3H5AaR3BvHYK7fwR3/wju/hHc/SO4+0dwzxeCex00PEbztVvNmDEjvKb7Edxbh+DuH8HdP4K7fwR3/wju/hHc84XgjkyKEtzfe++9oCZNmhS82dhynhHc/SO4+0dw94/g7h/B3T+Ce74Q3Bugse3qcdeQGYXZMihCcD/ppJPc4osvnlqVTnqSBwR3/wju/hHc/SO4+0dw94/gni8E9wx6enrc9OnTg/Hsmv5RAVal4K4AXwZFGypTJAR3/wju/hHc/SO4+0dw94/gni8E9xrsIFQFdgX3qVOnlmo2GUNwbx2Cu38Ed/8I7v4R3P0juPtHcM8XgnsNFtrVs66DUw3BHb4Q3P0juPtHcPeP4O4fwd0/gnu+ENxrUO+6etnV267gqrKx7ZpVZu7cueGa3Y3g3joEd3/eeuutoNZff333wAMPRMtoHsHdP4K7P+ecc05Qm2++uRs3bly0jOYR3POF4F4n9brrbKnDhw+PgnwZENz92nTTTd3gwYODWmaZZaLLG2ywQbgG6rXddtu5fv36BbXkkktGl1Xz5s0L10KjCO7+Edz9eOaZZ9zBBx+cWmgewT1fCO5NUG97fPhMNyO4+6V956mnnlqonn/++XANIF8I7v4R3FEEBPd8IbgjE4I7UD46Y/Syyy4bVN++faPLqo8++ihcC40iuKMICO75QnBHJgR3oJxee+211ELzCO4oAoJ7vhDckQnBHQD8IrijCAju+UJwRyYEdwDwi+COPLvxxhuD+upXv+rGjBkTLaOzCO7IhOAOAH4R3JFXmihBB6SnlabJRucQ3JEJwR0A/CK4A6gXwR2ZENwBwC+CO4B6EdyRCcEdAPwiuAOoF8EdmRDcAcAvgjuAehHckQnBHQD8IrgDqBfBHZkQ3AHAL4I7gHoR3JEJwR0A/Jg3b15QEydOdCeeeGK0DAC1ENyRCcEdAJq39957u+WWWy61/vrXv4ZrAUA6gjsyIbgDAAB0FsEdmRDcAQAAOovgjkwI7gAAAJ1FcEcmBHcAAIDOIrgjE4I7AABAZxHcC0TB2WrkyJFh68Li66k05VizCO4AAACdRXAvCAX1KVOmhEvODRo0aIHlOAXsmTNnhkt+ENwBAAA6i+BeAD09PUFo1k+j0F6p153gDgAA0H0I7gWgEK7QHDd9+vSg1z2N1o1XoyE+eTsURVEURZW70Fk8AzmkMen2AlGver3BPU7rNfpCs8dAURRFURSlQmfxDBRAvUNlkpK/2yjdTt++fcOl/CrSm4se51JLLRUu5VfRtuniiy8eLuVX0bbpoosuGi7lW1G2qx5j7969w6V8K9I2ZT/169hjjy3E4ywTno2CSB6MqheSetNr0e9k6ZnPQve5zDLLhEv51a9fv6CKoFevXoX4MlSkbaowtOSSS4ZL+VWkbaowtNhii4VL+VaU7artWZTgXpRtyn7qH8E9f3g2CsJ63a3iUzwqnNsLy4bGxMsXvcnoRQx/1llnHbf//vuHS/Bhiy22cKNHjw6X4MOYMWPcRhttFC7Bh4MPPtitvPLK4RJ8GDt2rNtwww3DJfhAcM8fng0AAACgAAjuAAAAQAEQ3AEAAIACILgDAAAABUBwBwAAAAqA4A4AAAAUAMEdAAAAKACCOwAAAFAABHfUFD+Z08iRI8NWNGvmzJlsU4/i+6kKjdGZltO2n/ZT27a+zsZcFrbtdCK9JNvebNfsqu2LyZMQZjnDOFxwUsf4dktjJ3uMn8Ud7cenG6rSG2T8Rao3SV60fugNUG+WBPfmJfdTLcfPLoza7IukBZ84tfE+UD8747Vt02RwZzvWr9q+aNvbtrPt02lfmPBf2k7x98u090+to22dfK9F+xHcUVHyTVD0giVoNk/b0D6A2J7N04dM/MMkuYzsLOxUo+2b/GBHZWnvpRaE0Jz4vpj2fqptrPdaZJe2HW3/VTvvrZ1FcEdFaR/gegPkw6Y52ob2ppj2BonGaL/U/qrig6VxWYK7trXWQzaVOkFsf7Xiy1D94vti2hdKgmb9tM3iX3a0TW0bsj07j+COigju/tkHuNEbIMG9ebZd7UuRLsdDErKrFdzTwhGqqxTc4699W4cvRNkl98W0fZOgWZ/kfhnvaBK2Z+cR3FFRlg8b1EdvgtqmaYXGafvFAw9fMBtXLbjrtU9or1/ae2kyEAn/ycgubV9M+3zSNtW2Rm3ansntpzb7jIpXcj20D2kBVelNL/7tWi9Y3gT94YuQH8n9UtuV4N6YSsE9+V6A7NKCe7Kt2hcmLKjSvmjb0Lap3hPYptmkfRFKo/V4H+gs9mhUZR8uVvS2+UVw98M+sOMVD0mozUJOvOzLT6VeN1SXtl/Gt5te//F29tnaau2LyW2q5wDVJbeZVdr+SHDvPN55AQAAgAIguAMAAAAFQHAHAAAACoDgDgAAABQAwR0AAAAoAII7AAAAUAAEdwAAAKAACO4AAABAARDcAQAAgAIguAMAAAAFQHAHAAAACoDgDgAAABQAwR0AAAAoAII7AAAAUAAEdwAAAKAACO4AAABAARDcAQAAgAIguAMAAAAFQHAHAAAACoDgDgAAABQAwR0ASmbKlClukUUWCX4aaxs5cmTY4tzMmTMXWq9Rul3dFgCgcbyLAkDJ9PT0LBTSLVjHw7WFeQX4ZhHcAaB5vIsCQAkNGjRogSBtoT0e1CdOnLhQ2La25LpiPfRWWtfEg/v06dMXuN6WrbQMAFgYwR0ASsgCuMK2BW4L0DY0RuE+3itvPfAmHuytF99Cd/w2xYK7tcdvN3k/AIB0BHcAKCEL0Arj8UCuEK1KBnGxXvpkaV27jWTZlwAL7qpkSI9fp9sCAKQjuANASVmIthLrRbcgHg/SFurT2Pr6QpDGwrmtZ4He2BeFtOsAAP9BcAeAkor3dFtYtuEyqmRIjw+vSbIefBu3nmT3JdZzb18K4vdT7TYAoOwI7gBQUvGQHg/j1pbW8x0P+6p46I7fnpXdbjy4W++6/a71wlsBANLxDgkAAAAUAMEdAAAAKACCOwAAAFAABHcAAACgAAjuAAAAQAEQ3AEAAIACILgDAAAABUBwBwAAAAqA4A4AAAAUAMEdAAAAKACCOwAAAFAABHcAAACgAAjuAAAAQAEQ3AEAAIACILgDAAAABUBwBwAAAAqA4A4AAAAUAMEdAAAAKACCOwAAAFAABHcAAACgAAjuAAAAQAEQ3AEAAIACILgDAAAABUBwBwAAAAqA4A4AAAAUAMEdAAAAKACCOwAAAFAABHcAAACgAAjuAAAAQAEQ3AEAAIACILgDAAAABUBwBwAAAAqA4A4AALrS2LFj3SKLLOKmTJkStgDFRnAHgA5SoBg0aFAQLlTDhw93M2fODK/9r+R6CiSzZs0Kr3Vu8uTJBBR0hayvialTpwbXxdebMWNGeO1/TJ8+Pbiuf//+YQtQbAR3AOgQ6w1Mq3gor7SewkhPT0+wjn5a29y5c4M2oGiyviYmTpyYuo4qGfL1mlB7MtQDRURwB4AOUAixoKGeQ1H4tpChYCLx9aw3XcHE2tTTbqz3Ub2MQNFkfU2IAr5eD/YlNR74k/91suvivw8UFcEdADogHr7jbMiLQrgohGhZ4SVu5MiRQbt+GltXQQUomqyviTTx300Gd3tdaPgNUHQEdwDogHjQsH/hq/cwPgRArLcwHtDFwky8XbejNgIKiijrayJNfB3dTlylLwRAEbEXo7Auv/xyt/zyywdvxosvvrgbPHiwe+yxx8Jr/bIPheQQBOvJaeXQBIWwvASxtF5esfZ4xT88k9fH2Ta0Sn7otpN9wCd77FpBgcSGAFQqqbTNbbvF2wko//Xcc8+5ww8/3G233XZBT+0OO+zgTjnlFPfGG2+Ea7RGtddCq/cvOxDT9/tRu96Dsr4mkuL7fdpwmPj18XHyQBHx7o5CiveuxKtXr15u9uzZ4Vr+2Bt/Mjzpw0ztrVTPh6Z9cLciGOh27faT20HLlR6jPVd2EKUu27rJoGGhx9ZtN3us7aIQER+bq4Bp28CGBdhycpsT3Ct76aWX3E477eSmTZvm5syZ415//fUgyJ966qlu3Lhx7q233grX9C+5D9t7hJaLGNztMfu8zWqyvCbitL6F/bTrJf660GWgyAjuyI1jjz02enNtV5111lnhvdcW/wAW/dRyvIfHwpSVhSpb15aTH7DxDxZV/DZ1v/FQXOk+7DbjZY/VPvis4sFBtx3/IlRN8u8wWo4/xrjk+vZYdFt22djfVikk2PXxbaDHHl+O/23J7apKPva45PW6bGW/3+oAY8+F7QP2t1Ua4x4fzx7/e7vRGWecUbP0mt5+++2D/8ilOfLII92YMWPc2Wefnfr7yaqXPS/22rPnU8+NPT+2j8b3W1XyNRTf7+L7dbxdZfdl7wHx13O121TFbzeN3VbyPuKPXbfZSsnXhIm/5+k6O1A1Kf66oMcdRUdwR27kPbjbB5UFN1vWh4LYh4hdX+lD2tazDzsLw8nfs2V98NqHb637sOttWZIfvMnHrduO32Y19liTH9TJMGCPN239+OOx+zbJvy/JHrt9gNtt2bI9Dvtb09atJLktxW7PHk/y8SbZ9cmqRON47bEqdGgmDfsde35s3LrKHoc91nibxNu7kYbE1apFF13ULbHEEu7BBx8Mf2tBN9xwQ7B90n43reqV3Adtn9Bych+z51iS+77tr/HbEbXbZdH92bLdRnLZ7i95m8n3gjS6rfj92W3aa9puwx53Gl2frPhtxmV5TYg9DpW9xivp9tcFyoW9GLmR9+CuDxP9jn1gJT/Q7AM7Lr6+aH277+SHZ7LswzZ+P7XuI/lBLfHrJRkekn9HNcltkMYegz5M09aPhwfbHsZ+t1IIsG1lH+DJZbttW9Zl+1C36ypJu+/k9rZle+6apdtKK3vMRkMA0tZTe7yXsdsPTr377rtr1v333+8mTJjgzjzzzPC3FnTggQe6E044wT3wwAOpv5+setk+Ei/bX5KvPdvn4mXX6XLa6yy5vpUk9+Hk6y9+WZKPJ03yd5L3YcvVbqMeuq20Sr4m6hkLb+8T3fq6QLlU/hQDcmzUqFELvVGrdt99d7fvvvuGa/lnH8ppH1Z2XZyW4x96WraqFD6T4sG61n2kPa749ZL8sI7ffi1pQTypVljQZbUlL0utbZG8PrmcDO52+1aVbleSgUSSj8+WKwV3bUe7r3hVoscf/x3dfvz+jcK5/jYLK/qp5eTQAJtppuzTQc6bN8/tsssu7rzzznN/+9vfgjHuTz/9dDBMRqF+/vz54Zr+VdtHtP/pOnvt2XMuyddu/Lq4Su2S3IfzEtx1fbIqvedkfU1Ueq1ZxdmY+WT4B4qo8icKkGOvvfaaW3XVVd0aa6wRvCFvsskmwbjVddddN7jOt1f/7z7mP/xw9CEV/3B4+3vfC66/4/OfD9qSH2hq1/U3bLRRsGwflvbB9Zc994yuT3PmcssF1+t+9KGWvI9j/m/Zrk/7IL584MDg+pcOOCBYToZbu/03/+/D7YMaB/ZmCe72GO0xaF0tW5CJ/37y77F1K7H17bEnl+N/mz1Wu+1a0rZd8vEk/5a8sZ75rH9zN9OXmh/84AfBeHdtl9GjR7vzzz/fvfvuu+EarVFtH4nvY7Z/Wpi0fdf2v+TtaNl+Vrp9Pe+6zt5bbLnSbSbfC9Lotuz2xG7T9rHkfeSN9gM9PpVNMQkUGcEdhaWZIdS7vsEGGwSly62aLeKdCy90r2++eXDZenr0offO8ce7N8ePd+/fe2/w89rPfjb6kFDdMmJE0P7A1Klu6v8t63rRh1z8+hn/dzu6/vDw91T6MNXtX9Wvn9t59dWD9bRsH7YqrX/fsGHR/et6e3wqe3z6/fjt2we13f72a67p3thjDzdv8GD34fPPB9cl2W3Gyz6sK7Wb+HXxECAWJqzSAomx7WaPP7mcDCLxbWFl16XR9RaQxB6bqRaaOk0H3emxqTc+2ROP9qm2j2jf03X2+rD9V2X7avy1Y9epLChLcr+2fTYeopPXmeTvVns9iL2m7O8pWnC3x5d83wGKiuAOZPTml7/s3j7xxHDJuQ/++tegp1o/u2FZ9Pfp7+wG9oFtwUTBQ8sKIpVYSCmaDz74IHrseQ1QKCb7smFBvWjsixSvC3QLgjuQkXqi1SOtnun5jz4a9XDHWQ93vAc8Lu/Xi/6z8O6FF4ZLxZbsXazV65bsEc07/T30JKLV2M+A/CC4A3XQGHCNBVdPtcaUp7Ex70W9XmP53zn77HAJAADkBcEdAAAAKACCOwAAAFAABHcAAACgAAjuAAAAQAEQ3AEAAIACILgDAAAABUBwBwAAAAqA4A4AAAAUAMEdAAAAKACCOwAAAFAABHcAAACgAAjuAAAAQAEQ3AEAAIACILgDAAAABUBwBwAAAAqA4A4AAAAUAMEdAAAAKACCOwAAAFAABHcAAAAg95z7/z+D1nen3efxAAAAAElFTkSuQmCC" alt="" width="750" height="463" vspace="0" hspace="0" border="0" style="width:750px;height:463px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>Paediatric population</u></p><p>The safety and effectiveness of OXBRYTA for sickle cell disease have been established in paediatric patients aged 12 years and older. Use of OXBRYTA for sickle cell disease is supported by evidence from an adequate and well-controlled study in adults and paediatric patients (HOPE trial). The HOPE trial enrolled a total of 29 paediatric patients aged 12 to &lt; 18 years, in which 14 paediatric patients received OXBRYTA 1500 mg once daily and 14 paediatric patients received OXBRYTA 900 mg once daily (see Section 4.8). The safety and efficacy of OXBRYTA in paediatric patients below the age of 12 years have not been established.</p><p>Pharmacokinetics, safety and efficacy in paediatric patients 12 years to &lt; 18 years were similar to that observed in adults (see Section 4.2) The adverse reactions observed in paediatric patients 12 to &lt; 18 years treated with OXBRYTA were similar in type and frequency to those observed in adults (see Section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voxelotor is absorbed into plasma and is then distributed predominantly into RBCs due to its preferential binding to Hb. The major route of elimination of voxelotor is by metabolism with subsequent excretion of metabolites into urine and faeces. The PK are linear and voxelotor exposures increased proportionally following either single or multiple doses (Table 3) in whole blood, plasma, and RBCs. Steady-state after repeated administration is reached within 8 days and</p><p>&nbsp;</p><p>exposures of voxelotor are consistent with accumulation predicted based on single dose data in patients with SCD.</p><p>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetics parameters of voxelotor in plasma and whole blood</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>PK parameter</strong></p></td><td style="vertical-align:top"><p><strong>Voxelotor 1500 mg Geometric mean (%CV)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Plasma PK</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC0-24h (&mu;g&times;hr/ml)</p></td><td style="vertical-align:top"><p>246 (27.7)</p></td></tr><tr><td style="vertical-align:top"><p>Cmax (&micro;g/ml)</p></td><td style="vertical-align:top"><p>12.6 (24.8)</p></td></tr><tr><td style="vertical-align:top"><p>Half-life (hours)</p></td><td style="vertical-align:top"><p>35.5 (25)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Whole Blood PK</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC0-24h (&mu;g&times;hr/ml)</p></td><td style="vertical-align:top"><p>3820 (35)</p></td></tr><tr><td style="vertical-align:top"><p>Cmax (&micro;g/ml)</p></td><td style="vertical-align:top"><p>179 (33.1)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>The median plasma and whole blood Tmax of voxelotor after oral administration is 2 hours. The mean peak concentrations in whole blood and RBCs are observed between 6 and 18 hours after oral administration.</p><p><u>Effect of food</u></p><p>A high-fat, high-calorie meal increased voxelotor AUC by 42% and Cmax by 45% in whole blood relative to AUC and Cmax in the fasted state. Similarly, AUC increased by 42% and Cmax increased by 95% in plasma.</p><p><u>Distribution</u></p><p>Voxelotor apparent volume of distribution of the central compartment and peripheral compartment are 338 L and 72.2 L in plasma, respectively. Protein binding is 99.8% in vitro. The blood-to-plasma ratio is approximately 15:1 in patients with SCD.</p><p><u>Biotransformation</u></p><p>In vitro and in vivo studies indicate that voxelotor is extensively metabolized through Phase I (oxidation and reduction), Phase II (glucuronidation) and combinations of Phase I and II metabolism. Oxidation of voxelotor is mediated primarily by CYP3A4, with minor contribution from CYP2C19, CYP2B6, and CYP2C9.</p><p><u>Elimination</u></p><p>The geometric mean (%CV) terminal elimination half-life of voxelotor in patients with SCD is</p><p>35.5 hours (25%) with concentrations in plasma, whole blood, and RBCs declining in parallel. The apparent oral clearance of voxelotor was estimated as 6.7 L/h in plasma in patients with SCD.</p><p>&nbsp;</p><p>Specific populations</p><p>No clinically significant differences in the pharmacokinetics of voxelotor were observed based on age (12 to 59 years), sex, body weight (28 to 135 kg), or mild to severe renal impairment (creatinine clearance [CLcr] 15&ndash;89 ml/min).</p><p><u>Paediatric patients</u></p><p>The pharmacokinetic parameters of voxelotor were similar in paediatric patients 12 to &lt; 18 years and adults.</p><p><u>Patients with renal impairment</u></p><p>There was no clinically significant effect of renal function on the excretion of voxelotor. Following a single 900 mg dose of voxelotor, whole blood exposures in subjects with severe renal impairment (eGFR &lt; 30 ml/min/1.73 m<sup>2</sup>) were 25% lower compared to healthy controls.</p><p>The unbound plasma concentrations were comparable. OXBRYTA has not been evaluated in patients with end stage renal disease requiring dialysis.</p><p><u>Patients with hepatic impairment</u></p><p>The voxelotor AUC in whole blood were 14% and 15% higher in subjects with mild and moderate hepatic impairment (Child Pugh A and B) and 90% higher in subjects with severe hepatic impairment (Child Pugh C) compared to subjects with normal hepatic function. For patients with severe hepatic impairment (Child Pugh C), the recommended dosage of voxelotor is 1000 mg taken QD with or without food. No dosage adjustment of voxelotor is required for patients with mild or moderate hepatic impairment.(See <em>Posology and method of administration </em>[Section 4.2])</p><p><u>Patients with HbSC genotype</u></p><p>Voxelotor steady state whole blood AUC and Cmax were 50% and 45% higher in HbSC genotype patients (n=11) compared to HbSS genotype (n=220) patients and voxelotor steady state plasma AUC and Cmax were 23% and 15% higher in HbSC genotype patients compared to HbSS genotype patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Voxelotor is absorbed into plasma and is then distributed predominantly into RBCs due to its preferential binding to Hb. The major route of elimination of voxelotor is by metabolism with subsequent excretion of metabolites into urine and faeces. The PK are linear and voxelotor exposures increased proportionally following either single or multiple doses (Table 3) in whole blood, plasma, and RBCs. Steady-state after repeated administration is reached within 8 days and</p><p>&nbsp;</p><p>exposures of voxelotor are consistent with accumulation predicted based on single dose data in patients with SCD.</p><p>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetics parameters of voxelotor in plasma and whole blood</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>PK parameter</strong></p></td><td style="vertical-align:top"><p><strong>Voxelotor 1500 mg Geometric mean (%CV)</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Plasma PK</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC0-24h (&mu;g&times;hr/ml)</p></td><td style="vertical-align:top"><p>246 (27.7)</p></td></tr><tr><td style="vertical-align:top"><p>Cmax (&micro;g/ml)</p></td><td style="vertical-align:top"><p>12.6 (24.8)</p></td></tr><tr><td style="vertical-align:top"><p>Half-life (hours)</p></td><td style="vertical-align:top"><p>35.5 (25)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Whole Blood PK</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC0-24h (&mu;g&times;hr/ml)</p></td><td style="vertical-align:top"><p>3820 (35)</p></td></tr><tr><td style="vertical-align:top"><p>Cmax (&micro;g/ml)</p></td><td style="vertical-align:top"><p>179 (33.1)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>Absorption</u></p><p>The median plasma and whole blood Tmax of voxelotor after oral administration is 2 hours. The mean peak concentrations in whole blood and RBCs are observed between 6 and 18 hours after oral administration.</p><p><u>Effect of food</u></p><p>A high-fat, high-calorie meal increased voxelotor AUC by 42% and Cmax by 45% in whole blood relative to AUC and Cmax in the fasted state. Similarly, AUC increased by 42% and Cmax increased by 95% in plasma.</p><p><u>Distribution</u></p><p>Voxelotor apparent volume of distribution of the central compartment and peripheral compartment are 338 L and 72.2 L in plasma, respectively. Protein binding is 99.8% in vitro. The blood-to-plasma ratio is approximately 15:1 in patients with SCD.</p><p><u>Biotransformation</u></p><p>In vitro and in vivo studies indicate that voxelotor is extensively metabolized through Phase I (oxidation and reduction), Phase II (glucuronidation) and combinations of Phase I and II metabolism. Oxidation of voxelotor is mediated primarily by CYP3A4, with minor contribution from CYP2C19, CYP2B6, and CYP2C9.</p><p><u>Elimination</u></p><p>The geometric mean (%CV) terminal elimination half-life of voxelotor in patients with SCD is</p><p>35.5 hours (25%) with concentrations in plasma, whole blood, and RBCs declining in parallel. The apparent oral clearance of voxelotor was estimated as 6.7 L/h in plasma in patients with SCD.</p><p>&nbsp;</p><p>1.1.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Specific populations</p><p>No clinically significant differences in the pharmacokinetics of voxelotor were observed based on age (12 to 59 years), sex, body weight (28 to 135 kg), or mild to severe renal impairment (creatinine clearance [CLcr] 15&ndash;89 ml/min).</p><p><u>Paediatric patients</u></p><p>The pharmacokinetic parameters of voxelotor were similar in paediatric patients 12 to &lt; 18 years and adults.</p><p><u>Patients with renal impairment</u></p><p>There was no clinically significant effect of renal function on the excretion of voxelotor. Following a single 900 mg dose of voxelotor, whole blood exposures in subjects with severe renal impairment (eGFR &lt; 30 ml/min/1.73 m<sup>2</sup>) were 25% lower compared to healthy controls.</p><p>The unbound plasma concentrations were comparable. OXBRYTA has not been evaluated in patients with end stage renal disease requiring dialysis.</p><p><u>Patients with hepatic impairment</u></p><p>The voxelotor AUC in whole blood were 14% and 15% higher in subjects with mild and moderate hepatic impairment (Child Pugh A and B) and 90% higher in subjects with severe hepatic impairment (Child Pugh C) compared to subjects with normal hepatic function. For patients with severe hepatic impairment (Child Pugh C), the recommended dosage of voxelotor is 1000 mg taken QD with or without food. No dosage adjustment of voxelotor is required for patients with mild or moderate hepatic impairment.(See <em>Posology and method of administration </em>[Section 4.2])</p><p><u>Patients with HbSC genotype</u></p><p>Voxelotor steady state whole blood AUC and Cmax were 50% and 45% higher in HbSC genotype patients (n=11) compared to HbSS genotype (n=220) patients and voxelotor steady state plasma AUC and Cmax were 23% and 15% higher in HbSC genotype patients compared to HbSS genotype patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Colloidal silicon dioxide Croscarmellose sodium Magnesium stearate Microcrystalline cellulose Sodium lauryl sulphate</p><p><u>Tablet film-coating</u> Polyethylene glycol 3350</p><p>&nbsp;</p><p>Polyvinyl alcohol Talc</p><p>Titanium dioxide Yellow iron oxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                48 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at or below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High-density polyethylene (HDPE) bottle with a polypropylene child-resistant closure and a silica gel desiccant canister and an appropriate length of polyester coil.</p><p>For US: Pack-size of 90 film-coated tablets. Additional Pack sizes will be determined on country by country basis</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GLOBAL BLOOD THERAPEUTICS, INC.
181 Oyster Point Boulevard, Suite 300 South San Francisco, CA 94080
USA

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mar / 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>